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A comprehensive summary of the work to be incorporated in the thesis entitled
“DESIGN AND SYNTHESIS OF HETEROCYCLES OF PHARMACEUTICAL
INTEREST” has been described as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON MICROWAVE INDUCED ORGANIC
REACTION ENHANCEMENT
[A] STUDIES ON PYRAZOLES
Literature survey reveals that nitrogen containing heterocyclic compounds like
pyrazoles  have received considerable attention in recent years due to their biological
and pharmaceutical activities like antiinflammatory, antitumor, fungicidal, antitubercular,
amoebicidal, herbicidal,  anticonvulsant, hypnotic, CNS depressant, plant growth
regulatory activity etc.
 Our efforts are focused on introduction of chemical diversity in the molecular frame
work in order to synthesizing active molecule of widely different composition. Prompted
by these facts, we have designed and synthesized some novel chalcones, pyrazolines,
arylidines, pyrimidines, cyanopyridines, cyanopyridones, isoxazoles, imidazolinones,
acetonitriles and azomethines bearing pyrazole nucleus. The study is described in the
following parts.
PART-I :  STUDIES ON PYRAZOLINES
Pyrazoline derivatives represent one of the modest class of compounds  possessing
wide range of pharmacological activities like antibacterial, analgesic, anthelmintic,
antiinflammatory, antitubercular etc. These valid observations led us to synthesise some
novel pyrazoline derivatives bearing 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole
moiety, which have been described as under.
















                                                          Type (II)                   R = Aryl
The chalcone derivatives of type (I) have been prepared by the condensation of
1,N-phenyl-3-p-ethoxyphenyl-4-formyl pyrazole with different aryl ketones in the
presence of 40% NaOH.
SECTION -II : Synthesis and biological evaluation of 3-Aryl-5-(1',N-
phenyl -3'-p-ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
The pyrazoline derivatives of type (II) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate.



















                                                          Type (IV)                   R = Aryl
The pyrazoline derivatives of type (III) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
PART-II :  STUDIES ON PYRIMIDINES
The emerging role of pyrimidines in pharmaceutical chemistry as well as in
biochemistry stimulated tremendous interest in the synthesis of pyrimidines with therapeutic
potential.
In order to achieving better therapeutic activity, we have synthesised some new
pyrimidine derivatives bearing pyrazole nucleus which is described as under.
SECTION–I : Synthesis and biological evaluation of 2-Arylimino-3,N-





























                                                          Type (VI)                   R = Aryl
The arylidines of type (IV) have been prepared by condensation of 1,N-phenyl-
3-p-ethoxyphenyl-4-formyl pyrazole with different thiazolidinones in glacial acetic acid.
SECTION–II : Synthesis and biological evaluation of 6-Arylimino-7,N-
aryl-2-oxo-4-(1’,N-phenyl-3’-p-ethoxyphenyl pyrazol-4’-
yl)-1,2,3,4-tetrahydro thiazolidino-[4,5-e]-pyrimidines.
Pyrimidinones of type (V) have been prepared by the condensation of 2-
arylimino-3,N-aryl-5-(1’,N-phenyl-3’-p-ethoxyphenyl-4’-pyrazolylmethino)-4-
thiazolidinones with urea in glacial acetic acid with fused sodium acetate.
SECTION–III : Synthesis and biological evaluation of 6-Arylimino-7,N-
aryl-2-thio-4-(1’,N-phenyl-3’-p-ethoxyphenyl pyrazol-4’-

















                                                          Type (VIII)                   R = Aryl
Pyrimidinones of type (VI) have been prepared by the condensation of 2-
arylimino-3,N-aryl-5-(1’,N-phenyl-3’-p-ethoxyphenyl-4’-pyrazolylmethino)-
4-thiazolidinones with thiourea in glacial acetic acid with fused sodium acetate.
PART-III :  STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivatives represents one of the modest classes of compounds
possessing wide range of therapeutic activities, such as antimicrobial, antimalarial and
antibacterial. With a view to getting better therapeutic agents and to evaluate it’s
pharmacological profile, different type of azomethine derivatives and  arylaminomethyl
derivatives have been prepared, which have been described as under.
SECTION-I : Studies on N-Aryl-1,N-phenyl-3-p-ethoxyphenyl pyrazol-
4-yl-azomethines
The azomethines of type (VII) have been prepared by the condensation of 1,N-
Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole with different aromatic amines.











                                                          Type (IX)                   R = Aryl
The compounds of type (VIII) have been prepared by the reaction of compounds
of type (VII) with an. NaBH4.
PART - IV : STUDIES ON IMIDAZOLINONES
Imidazolinone derivatives have been found to be potent drug in pharmaceutical and
possess a wide range of biological activities such as anticonvulsant, antiinflammatory,
hypnotic, sedative, antihistamine and antithyroid. In order to develop medicinally
important compounds, we have synthesised some new imidazolinones shown as under.
SECTION-I : Synthesis and biological evaluation of 1,N-Aryl-2-phe-
nyl-4-(1’,N-phenyl-3’-p-ethoxyphenyl-4’-pyrazolylmethine)-
imidazolin-5-ones
The imidazolinone derivatives of type (IX) have been prepared by the reaction of
azalactone with different aryl amine in pyridine.
PART - V : STUDIES ON CYANOPYRIDONES
The group of compounds containing cyanopyridone ring system have a prominent
feature in medicinal chemistry and possess biological activities such as analgesic,
antidiabetic, anticonvulsant, insecticidal and antibacterial etc. In view of these facts, it




















                                                          Type (XI)                   R = Aryl
SECTION - I : Synthesis and biological evaluation of 3-Cyano-4-(1',N-phe-
nyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-6-aryl-1,2-dihydro-2-
pyridones.
The cyanopyridones of type (X) have been prepared by the condensation of
chalcones of type (I) with ethylcyanoacetate and ammonium acetate.
PART-VI : STUDIES ON CYANOPYRIDINES
Cyanopyridine plays a vital role owing to their wide range of biological activities
such as antihypertensive, antibacterial, antidiabetic and anticholestemic. They have been
also used as dyes for cotton and polyester fabrics.It appeared of interest to design and
synthesise cyanopyridine derivatives, which have been described as under.










                                                          Type (XII)                   R = Aryl
2- Methoxy-3-cyanopyridines of type (XI) have been prepared by the
condensation of chalcones of type (I) with malononitrile and sodium methoxide.
PART-VII :  STUDIES ON ISOXAZOLES
It  has been reported that isoxazole derivatives possess remarkable
pharmacological importance and biological activities such as antifungal, antibacterial,
sedative and hypnotics etc. In order to developing medicinally important compounds we
have synthesized some new isoxazole derivatives shown as under.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-(1',N-phe-
nyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-isoxazoles
The isoxazole derivatives of type (XII) have been prepared by the reaction of
chalcones of type (I) with anhydrous sodium acetate and hydroxylamine hydrochloride
in glacial acetic acid.
PART - VIII : STUDIES ON a-ARYLAMINONITRILES
Recently substituted nitrile derivatives have drawn considerable attention due to
their good pharmacological activities like cardiovascular, sedative, antifungal and anti-
bacterial. By considering these valid observations, we have synthesised some new ni-
triles which have been described as under.










                                                          Type (XIII)                 R = Aryl






The nitriles of type (XIII) have been prepared by the condensation of 1,N-phenyl-
3-p-ethoxyphenyl-4-formyl pyrazole with different aromatic amines in presence of sodium
cyanide and glacial acetic acid at 0-5 0C.
[B] STUDIES ON MICROWAVE INDUCED ORGANIC
REACTION ENHANCEMENT
In the recent years,  MORE (Microwave Induced Organic Reaction
Enhancement) technique has become very popular due to substantial reduction in reaction
time, operational time, operational simplicity and formation of clear reaction products.
Keeping this in view, we investigated the synthesis of acetyl pyrazolines and cyano
pyridines using microwave irradiation.
PART - I : STUDIES ON ACETYLPYRAZOLINES













                                                          Type (XI)                   R = Aryl
The pyrazoline derivatives of type (III)have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid under microwave irra-
diation in few minutes.The results obtained are compared with traditional synthetic method.
PART - II : STUDIES ON CYANOPYRIDINES
SECTION–I : Synthesis and biological evaluation of 2-Methoxy-3-
cyano-4-(1’,N-phenyl-3’-p-ethoxyphenyl–pyrazol-4’-yl)-6-
aryl-pyridines
2- Methoxy-3-cyanopyridines of type (XI) have been prepared by the
condensation of chalcones of type (I) with malononitrile and sodium methoxide under
microwave irradiation in few minutes. The advantages of microwave synthesis has been
reported.The results obtained are compared with traditional synthetic method.
CHARACTERISATION :
The constitution of newly synthesised products have been supported by  using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and further





Dr. (Mrs.) H. H. Parekh
Signature of Candidate
(Nandalal V. Shekhada)
In vitro study on multiple biological activities :
(i) All the compounds have been evaluated for their antibacterial activity  towards
Gram positive  and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 mg. The biological activity
of  the synthesised compounds have been  compared with standard drugs.
(ii) Selected compounds have been evaluated for their in vitro biological assayv
like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 mg/ml using Rifampin as a standard drug,which
have been tested by Tuberculosis Antimicrobial Acquisition Coordinating
Facility (TAACF), Alabama,U.S.A.




Research in the field of pharmaceutical has its most important task in the
development of new better drugs and their successful introduction into clinical practice.
Central to these efforts, accordingly stand the search for pharmaceutical substances and
preparation which are new and original. In addition to these objectives, we may search
for newer drugs which exhibit some clear advantages over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effects, lower toxicity, improved stability or decreased cost.
The word ‘drug’ is derived from the French word ‘drogue’ which means a dry
herb. According to “WHO” a drug may be defined as “any substance or product which
is used or intended to be used for modifying or exploring physiological system or
pathological status for the benefit of recipient”.
In the nineteenth century, chemistry was developed as a science, both in terms of
experimental procedures and scientific theory. Scientist isolated and purified single
compounds from natural extracts. Method of organic synthesis were developed that
helped chemists altering structures in a predictable way.
Chemistry related with pharmaceutically important compounds is mainly
divided in two parts. The first, chemotherapy, concerns the treatment of infections,
parasites or maligant diseases by chemical agents, usually substances that shows selective
toxicity towards the pathogen. The other division relates to diseases of bodily disfunction
and the agents employed are mainly compounds that effect the functioning of enzymes,
the transmission of nerve impulses or the action of hormones on receptors.
A prerequisite for the design of safe drugs is knowledge about the various
metabolic reactions that xenobiotics and endogenous compounds undergo in the organism.
Because pharmacological activity depends on molecular structure, the medicinal chemist
is restricted in the choice of functional groups for the design of new drugs. Often he
12
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finds or she encounters a situation where a structure has  adequate pharmacologic activity
but has an inadequate pharmacokinetic profile (i.e., absorption, distribution, metabolism
and excretion). This is because pharmacology and pharmacokinetic departments in the
pharmaceutical industry often do not collaborate at the early stage of drug development.
It is only later, when the new compound is tested in animals or in humans, that
pharmacokinetic disadvantages  become obvious.
A large number of important drugs have been introduced during the period of
1940 to 1960. This perod is known as ‘Golden Period’ of new drug discovery. Thus
starting from 1933-the first antibacterial drug prontosil leading to various sulpha
drugs; 1940-penicillin, antibiotics; 1945-chloroquine, antimalarial;1957-chlorthiazide,
diuretic; 1958-adrenergic beta blockers coronary vasodilatory; 1960-semi synthetic
penicillin, antibacterial1965- trimethoprim, antimicrobial;  1967-disodium
chromoglycoate, antiallergic; 1972-cimetidine, H2-antagonist; 1975-verapamil,
calcium antagonist;1981-captopril,antihypertensive. These are some specific
examples representing new therapeutics
Modern drug discovery starts with the identification of a pharmacologic   target
that is hypothetically the primary cause of disease. Potential targets include host cell
genes, receptors, signaling systems, organelles and biochemicals such as enzymes.
Additionally, an element of a disease modifying process, such as an inflammatory
mediator, may be a target. Biological processes required for propagation of infectious
agents have also proven to be therapeutically useful targets; examples include protease
and reverse transcriptase of the human immuno deficiency virus(HIV). Common to all
targets selected as therapeutic opportunities is the hypothesis that some type of
pathogenetic linkage exists to the disease- causing process, rather than to specific signs,
symptoms or effects.
Heterocyclic compounds have great applicability in pharmaceutics because they
have specific chemical reactivity and provides false synthons in biosynthetic process or
block the normal functioning of biological receptors. The inhibition of amide resonance
13
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resulting into more susceptibility of b-lactam to nucleophile is considered at least in part
responsible for antibacterial property, apparently by acetylating transpeptidase and thus
inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occurring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles. Most
of the sugars are their derivatives including Vitamin C for instance, exist largely in the
form of five membered. Vitamin B6 (Pyridoxine) is a derivative of pyrimidine essential in
aminoacid metabolism. .
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing pyrazole nucleus. The placement of a wide variety
of substituents of these nuclei have been designed in order to evaluate the synthesized
products for their pharmacological profile against several strains of bacteria and fungi.
AIMS AND OBJECTIVES
¨ To generate several derivatives like chalcones, pyrazolines, cyanopyridines,
cyanopyridones,  thiazolidinones, pyrimidines,  imidazolines, arylaminomethyl
derivatives, acetonitriles bearing pyrazole nucleus. bearing pyrazolemoiety.
¨ To synthesise biologically active pyrazolines and methoxy pyridines using
microwave induced synthesis method.
¨ To characterize these products for structure elucidation using spectroscopic
technique like IR, PMR and Mass spectral studies.
¨ Purity of all compounds have been checked by thin layer chromatography.
¨ To evaluate these new product for better drug potential against different strain of
bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37Rv.
14
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Pyrazoles are well known five membered heterocyclic compounds which consist
of a doubly unsaturated five membered ring (I)containing two adjacent nitrogen
atoms.Knorr1 introduced the name pyrazole for these compounds to donate that the
nucleus was derived from pyrrole by replacement of carbon by nitrogen
Considerable interest has been focused on the pyrazoles derivatives which has
been known to possess a broad spectrum of biological activities such as tranquillizing,
muscle relaxant, psychoanaleptic, anticonvulsunt and antihypertensive activities.The
discovery of this class of drugs provides an outstanding case history of modern drug
development and also point out the unpredictability of biological activity from structural
modifications of a prototype drug molecule.
The knowledge of such applications has pointed out that N-substituted pyrazoles
are important targets to be prepared.  Knorr2,3 first synthesized a compound containing
this system in 1883 by a reaction of ethylaceto acetate with phenylhydrazine which yielded
1-phenyl-3-methyl-5-pyrazolone (II).
 since many drugs and dyes contain the pyrazole nucleus, the class has been
widely studied and the field continues to be active today.
SYNTHETIC ASPECTS
Various methods for the preparation of pyrazoles have been cited in literature.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
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2. R. C. Boruah4  et. al. suggested one pot synthesis of pyrazoles from-b-formyl
enamides.
3. M. J. Kurth5 et. al. suggested a novel route for synthesis of fully substituted
1H-pyrazoles.
4. The reaction of hydrazines with a,b-unsaturated carbonyl compounds.
5. The reaction of aliphatic diazo compounds such as diazomethane or diazoester
with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Pyrazole derivatives have been reported to be associated with diverse biological
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Much research has been carried out with the aim to finding therapeutic values of
pyrazole moiety since their discovery. A large number of substituted pyrazole derivatives
are prepared and tested for variety of biological activities like,
(a) Antiinflammatory6-7
(b)  Insecticidal8-9








Jansen Karte et al.18 have synthesized pyrazole derivatives as pesticides. Somega
Shinzo and co-workers19 have synthesized pyrazole derivatives and reported their
herbicidal activity. Geheing Reinhald et al.20 have synthesized 5-amino-4-cyano-1-aryl-
pyrazoles and shown them as plant growth inhibitors. Nakamura Katsyga and co-
workers21,22 have prepared 1,5-diphenyl pyrazoles as Cox-2-inhibitors (IX).
Bernard Banks et al.23 have synthesized pyrazole derivatives (X) and tested for
their antiparasitic activity.
Menozzi G. and co-workers24 have synthesised a series of N-substituted
4-carboxy-1-phenyl-lH-pyrazole-5-propanamides, in which some of the compounds
showed a platelet antiaggregating activity in vitro superior or comparable to that of
acetylsalicylic acid, as well as moderate antiinflammatory, analgesic and antipyretic
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3-yl]-1H-pyrazole-4-acetic acids and their ethyl ester derivatives were prepared by
Giuseppe Daidone25 and tested for analgesic and antiinflammatory activities, acute
toxicity, ulcerogenic effect, and  in vitro inhibitors of 3a-hydroxysteroid dehydrogenase
(3a-HSD) . Ejima Akio et. al.26 have synthesized pyrazole derivatives as antitumor agents.
Laborde Edgardo et al.27 have found that pyrazoles possess glycine transporter-
2-inhibitor activity. Andrew Thurkaub et al.28 have synthesized high affinity C5a receptor
modulator pyrazoles. Nagaaki Sato et. al.29 have prepared arylpyrazole derivatives
and evaluated as neuropeptide Y5 receptor antagonist. One of the compound with chiral
2,3-dihydro-1H-cyclopenta[a]naphthalene moiety, showed good binding affinity and
antagonistic activity for the Y5 receptor. G. M. Hi Yamanonch30 has prepared pyrazoles
as glycine transporter protein inhibitors.
David L. S. et al31 have reported pyrazoles as activators of the nitrile oxide
receptor and soluble guanglate cyclase agent. T Van Herk et al.32 have demonstrate
pyrazoles as nicotinic acid receptor (XI). Barber Christopher et al.33 have synthesized
pyrazole derivatives as phosphodiesterase inhibitors.
Recently, Atkinson R. N. et al.34 have synthesized pyrazoles as sodium channel
Blocker (XII). Gellibert Francoise et al.35 have prepared pyrazole derivatives as TGF-
13 inhibitors.
Grazid Mamalo et al.36 have newly synthesized pyrazole derivatives tested for
antimicrobial activity. R. Y. Huang and co-workers37 have prepared some 1,2,4- triaryl-
4-alkyl-pyrazoles as estrogen receptor. C. Vittoria and co-workers38 have prepared
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Schindler Ursula et al.39 synthesized new pyrazole derivatives (XIII) as
cardiovascular agents. Carbau Romuald and co-workers40 have prepared pyrazole
derivatives (XIV) useful as reverse transcriptase inhibitors for the treatment of HIV
infection.
Ji Yang et al.41 have documented 3-(4-phenoxyphenyl)pyrazole
derivatives (XV) for their Sodium Channel Blockers. Ruoxi Lan et al.42 have prepared
pyrazole derivatives as Cannabinoid receptor antagonist.(XVI)
Akihiko Tanitame and co-workers43 have synthesized new pyrazole
derivatives and found that 5-[(E)-2-(5-chloroindol-3-yl)vinyl]pyrazole possesses potent
antibacterial activity and selective inhibitory activity against bacterial topoisomerases.
Many of the synthesized pyrazole derivatives were potent against clinically isolated
quinolone or coumarin-resistant Gram-positive strains. Gregory R. Bebernitz et al.44
have described 1,3-diaryl-[1H]-pyrazole-4-acetamide as antidiabetic agents (XVIII).
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Abdel-Rahman Farghaly and Hussein el-Kashef et al.46 have prepared pyrazole
derivatives as antibacterial and antifungal agent. Pierluigi Caboni  et al.47 have reported
phenylpyrazole insecticide photochemistry, metabolism and gabaergic action(XIX). Craig
W. Lindsley et al.48 have discovered positive allosteric modulators for the Metabotropic
Glutamate Receptor from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that
potentiate receptor function in vivo(XX).
Adrian l. Gill and Martyn Frederickson et al.49have identified pyrazoles as a
novel p38a MAP kinase inhibitors(XXI). Jeffrey roppe et al.50have discovered novel
heteroaryl azoles that are metabotropic glutamate receptor antagonists with anxiolytic
activity(XXII)
Recently, Bantwal Holla and co-workers51 have synthesised pyrazole
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methyl-1H-pyrazol-1-yl)-chloroquine analogues has been evaluated in vitro against a
chloroquine resistant Plasmodium falciparum clone by Antoniana U. Krettli et. al.52.
Pyrazole derivatives with nanomolar activity in the biochemical assay and able to
efficiently inhibit CDK2-mediated tumor cell proliferation have been  obtained by Paolo
Pevarello et. al.53.
Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activity, it appeared of interest
to synthesize some chalcones, pyrazolines, arylidines, pyrimidines, cyanopyridines,
cyanopyridones, isoxazoles, imidazolinones, acetonitriles and arylaminomethyl bearing
pyrazole moiety, in order to achieving compounds having better therapeutic importance.
These studies are described in following parts.
[A] STUDIES ON PYRAZOLES
PART - I : STUDIES ON PYRAZOLINES
PART - II : STUDIES ON PYRIMIDINES
PART - III : STUDIES ON ARYLAMINOMETHYLDERIVATIVES
PART - IV : STUDIES ON IMIDAZOLINONES
PART - V : STUDIES ON CYANOPYRIDONES
PART - VI : STUDIES ON  CYANOPYRIDINES
PART - VII : STUDIES ON  ISOXAZOLES
PART - VIII : STUDIES ON  a-ARYLAMINONITRILES
22
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Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful frame work for biological activities. Pyrazolines have
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry
and the pharmacological activities associated with them. In 1967 Jacobe, reviewed the
chemistry of pyrazolines, which have been studied extensively for their biodynamic
behavior1 and industrial applications.2
SYNTHETIC ASPECTS
Different methods for the preparation of 2-pyrazoline derivatives documented in
literature are as follows.
1. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcone.3
2. 2-Pyrazoline can be prepared by the condensation of a, b-unsatured ketone
and thiosemicarbazide in the presence of basic alumina and K2CO3.4
3. Dipolar cycloaddition of nitrileimines of dimethyl fumarate, fumaronitrile and the
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4. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine hydrate
and phenyl hydrazine to give pyrazolines.6
5. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazine.7
6. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate.8
Furthermore, B. Gyassi et al.62 have investigated one pot synthesis of some
pyrazolines in dry media under microwave irradiation. S. Paul et. al.63 and Dandia Anshu
et. al.64 have also described the microwave assisted synthesis of 2-pyrazolines.
MECHANISM
The following mechanism seems to be operable for pyrazoline by the condensation
of chalcones with hydrazine hydrate.65
Nucleophillic attack by hydrazine at the b-carbon of the a,b-unsaturated carbonyl
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Proton transfer from the nitrogen to negative oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophillic attack by the primary amino group of ketoamine on its carbonyl carbon
followed by proton transfer from nitrogen to oxygen leads to carbonyl amine (IV).The
later with a hydroxy group and amino group on the same carbon lose water molecule to
yield the pyrazolines.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better therapeutic















Shivnanda M. K. and co-workers83have prepared pyrazolines and reported their
antibacterial activity. E. Palska et al.84have prepared 3,5-diphenyl-2-pyrazolines (VII)





OMeR1 = H,Cl, Br, Me, MeO
R2 =H, Cl (VII)
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Moreover, F. Manna and coworkers85 have described 1-acetyl-5-(2'-
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazolines (VIII) and its
derivatives which acts as potent antiinflammatory, analgesic and antipyretic agents.
S. S. Sonarc et al.86 have synthesized 3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted-phenyl)-pyrazolines (IX) and tested their antimicrobial activity. V. V.
Fernandes et al.87 have also synthesized some new pyrazolines as an antimicrobial agent.
Udupi R. H. and Bhatt A. R.88 have reported the synthesis and biological activity
of Mannich bases of certain 1,2-pyrazolines. Nugent Richard89 investigated pyrazolines
bis phosphonate ester as novel antiinflammatory and antiarthritic agent. Furthermore,
Fuche Rainer et al.90 have prepared some new 1H-pyrazoline (X) derivatives and
reported them as pesticides. Tsuboi et al.91 have synthesized some new phenylcarbonyl
pyrazolines (XI) as an insecticides and at 40% concentration shows 100% mortality of
























    (XI)
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Tuntawy Atif and coworkers92 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agent. Almstead J. et al.93 have prepared
pyrazolines as vascularization agent. G. N. Mishirika et al.94 have also prepared
2-pyrazolines of salicylic acid (XII) possessing antimicrobial properties.
Maurer Fritz et. al.95 have synthesized pyrazolyl pyrazolines. In spodoptera
frugiperda pesticide studies with Brassica oleracea, at 500 ppm some of compounds
exhibited 100% mortality after seven days and some of compounds were claimed
to be useful as pesticidal coating material agents.
Gokhan N. et al.96 have synthesized the pyrazoline derivatives of 1-N-substituted
thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines as MAO inhibitors. Matysiak J. et al.97
have reported some novel pyrazoline derivatives as antimycotic activity of
N-azolyl-2,4-dihydroxythiobenzamides. Tabarelli Z. et. al.98 have prepared some
pyrazole derivative showing activity of antinociceptive effect of novel pyrazolines in  mice.
Tae-Sook Jeong et. al.99 have reported pyrazole as low-density lipoprotein (LDL)
oxidation inhibitor . One of the compound was 6-fold more potent than probucol in the
TBARS assay.
B. Bizzarri et. al.100 have reported in vitro selective anti-helicobacter pylori
activity of pyrazoline derivatives. Mohammad Abid and Amir Azam101have synthesized
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CONTRIBUTION FROM OUR LABORATORY
S. D. Sorthiya et. al.102 have synthesised and tested the antimicrobial activity of
p-(2',5'-Dibromobenzenesulphonamido)-phenyl-5-aryl-1H/acetyl/phenyl-2-pyrazolines.
Parekh et. al.103 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-4-one-
3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Parikh et. al.104 have synthesised some antimicrobial pyrazolines. Tejas Upadhyay
et. al.105 and Sohit Rajvaidya et. al.106 have prepared pyrazolines as antimicrobial
agent. A. V. Dobaria and Co-workers107 has discovered pyrazolines bearing
chloroquinoline nucleus which used as antimicrobial agents(XIV).
Recently, Abd El-Galil E. Amr et. al.108 have synthesised some new 3-substituted
androstano[17,16-c]-52-aryl-pyrazolines and reported their antiandrogenic activity.
Amir Azam and co-workers109 have synthesised some pyrazoline derivatives and
reported their antiamoebic activity.
 Some of the compounds were found with IC50 lower than that of the standard
drug metronidazole and thus are better inhibitor of growth of E. histolytica. Y. Rajendra
Prasad et. al.110 have synthesised some 1,3,5-triphenyl-2-pyrazolines and 3-(2’’-




















 R1, R2, R3, R4 = Alkyl
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Thus interesting biological activities of a novel heterocycles like pyrazolines have
stimulated considerable research work in recent years leading to the synthetic utility of
the derivatives of this ring system. In our search for new potential antimicrobial compounds,
the reaction series of chalcones with hydrazine hydrate/phenylhydrazine under different
conditions has been investigated and the pharmacological profile of the compounds have
been studied and described as under.
SECTION-I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
A RY L - 3 - ( 1 ' , N - P H E N Y L - 3 ' - p- E T H O X Y P H E N Y L -
PYRAZOL-4'-YL)-2-PROPEN-1-ONES
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3 -
A RY L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p- ETHOXYPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-
A C E T Y L - 3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p -
ETHOXY- PHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
29




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
The chemistry of chalcones have generated intensive scientific studies throughout
the world, specially interesting for their biological and industrial applications.With a view
to obtaining compounds with better therapeutic activity, we have synthesized 1-aryl-3-
(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-2-propen-1-ones by the condensation
of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole with various aromatic ketones in
the presence of 40 % NaOH.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological
assay  l ike  an t i tubercu la r  ac t iv i ty  towards  a  s t r a in  o f  Mycobac ter ium







Type (I)            R = Aryl
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Type - (I) R = Aryl
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
(A) Synthesis of p-Ethoxyphenylhydrazone111
A mixture of phenylhydrazine (1.08 g, 0.01 M) and p-ethoxyacetophenone (1.64
g, 0.01 M) in absolute ethanol was refluxed in water bath for 1 hrs. in the presence of
1ml glacial acetic acid. Product obtained after cooling was crystallised from absolute
ethanol. Yield 92%, m.p. 63oC (C16H18N2O; Required : C, 75.56;H, 7.13, N, 11.01;
Found : C, 75.51; H, 7.09; N,10.95%).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
p-Ethoxyphenylhydrazone(2.54 g, 0.01 M) was added into a Vilsmeier-Haack
reagent (prepared by dropwise addition of 3 ml POCl3 in ice cooled 25 ml DMF) and
refluxed for 5 hrs. The reaction mixture was poured on to crushed ice followed by
neutralization using sodium bicarbonate. Crude product was isolated and crystallised
from methanol. Yield 80%, m.p. 120oC (C18H16N2O2; Required : C, 73.95; H, 5.52;
N, 9.58;  Found : C, 73.89; H, 5.48; N, 9.52%).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
To a solution of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole (2.92 g, 0.01 M),
and p-bromoacetophenone (1.99 g, 0.01 M) in ethanol (25 ml) , 40% NaOH added till
the solution become basic. The reaction mixture was stirred for 24 hrs. The contents
were poured on to crushed ice. Upon neutralization the solid was separated and
crystallised from ethanol. Yield 65%, m.p.168oC (C26H21BrN2O2; Required : C,
65.97; H, 4.47; N, 5.92;  Found : C, 65.91; H, 4.41; N, 5.87%).
TLC solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly other 1-aryl-3-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-2-
propen-1-ones have been prepared. The physical data are recorded in Table No. 1.
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(D) Antimicrobial activity of 1-Aryl-3-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-
4'-yl)-2-propen-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method418
which has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of 24
hrs. old subcultures of B. coccus, S. aureus, E.aerogenes, P. aeruginosa in separate
conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml content of the
flask were poured and evenly spreaded in a petridish (13cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40mg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and are recorded in Graphical Chart No.1.
The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics like amoxicillin, benzoyl penicillin, ciprofloxacin and
erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud’s agar slants. Sterilized Sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a separate
flask. About 25 ml of the inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The cups (10 mm in diameter) were punched and filled with
0.04 ml (40 mg) solution of sample in DMF. The plates were incubated at 30oC for 48
33
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hrs. After the completion of incubation period, the zones of inhibition of growth in the
form of  diameter in mm was measured. Along the test solution in each petridish one cup
was filled with solvent which act as control. The zones of inhibition were compared with
standard antifungal greseofulvin. The zones of inhibition are recorded in Graphical Chart
No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition and Co-ordination Facility (TAACF), U.S.A. Primary screening
of the compounds for the antitubercular activity have been conducted at 6.25 mg/ml
towards Mycobacterium tuberculosis H37Rv in BACTEC 12B using the BACTEC
460 radiometric system. The compounds demonstrating atleast>90% inhibition in the
primary screening has been tested at lower concentration towards Mycobacterium
tuberculosis H37Rv to determine the actual minimum inhibitory concentration (MIC)
in the BACTEC-460.
The antitubercular activity data have been compared with standard drug rifampin
at 0.25 mg/ml concentration and it showed 98% inhibition.
34





Gram positive bacteria : B. coccus
S. aureus
Gram negative bacteria : E.aerogenes
P.aeruginosa
Fungi : A. niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl penicillin,
Ciprofloxacin, Erythromycin
Greseofulvin
The antimicrobial activity was compared with standard drugs viz amoxicillin,
benzoyl penicillin, ciprofloxacin, erythromycin and antifungal activity was compared with
viz greseofulvin. The inhibition zones were measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin.
The antitubercular activity data are showed in Table No. 1a.
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TABLE NO. 1a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute                      Dr. H. H. Parekh
Primary Assay Summary Report           Saurashtra University
 Sample Corp Where,R= Supplier Assay MTb MIC  % Activity
 ID ID Strain µg/ml Inhib
 295669 NV-3 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 97 +
 295658 NV-2 4-Cl-C6H4- Sau. uni. Alamar H37Rv >6.25 96 +
 295673 NV-7 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 94 +
 295678 NV-12 4-OCH3-C6H4 Sau.uni Alamar H37Rv >6.25 92 +
 295670 NV-4 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 61 -
 295677 NV-11 4-CH3-C6H4 Sau.uni Alamar H37Rv >6.25 44 -
 295667 NV-1 -C6H5 Sau.uni Alamar H37Rv >6.25 38 -
 295672 NV-6 3-NO2-C6H4 Sau.uni Alamar H37Rv >6.25 12 -
 295675 NV-9 4-NO2-C6H4 Sau.uni Alamar H37Rv >6.25 06 -
 295671 NV-5 2--C4H3S Sau.uni Alamar H37Rv >6.25 05 -
 295676 NV-10 4-NH2-C6H4 Sau.uni Alamar H37Rv >6.25 02 -
 295674 NV-8 4-OH-C6H4- Sau.uni Alama H37Rv >6.25 01 -
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Alkane C-H str. (asym.) 2966 2975-2950 413
-CH3 C-H str. (sym.) 2877 2880-2860
C-H i.p.def. (asym.) 1436 1470-1435
C-H o.o.p. def. (sym.) 1361 1390-1370
Aromatic C-H  str. 3070 3080-3030 414
C=C str. 1564 1585-1480
C-H i.p. def. 1093 1125-1090
C-H o.o.p. def   817 835-810
Pyrazole C=N str. 1596 1630-1590 415
moiety (overlapped)
C-N str. 1215 1230-1020
Ether C-O-C str. (asym.) 1215 1275-1200 413
(overlapped)
C-O-C str. (sym.) 1064 1075-1020
Chalcone C=O str. 1660 1685-1645 416
CH=CH 3070 3050-3000
(overlapped)





Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
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Multiplicity Inference J Value
In Hz
1. 1.44-1.46 3H triplet -OCH2CH3 JCH3=7.1
2. 4.07-4.14 2H quartret -OCH2CH3 JCH2=6.8
3. 7.00-7.02 2H doublet Ar-Hff ’ Jfg=8.7
4. 7.26-7.37 3H multiplet Ar-Hace        -
5. 7.40-7.52 2H triplet Ar-Hbd        -
6. 7.59-7.62 2H doublet Ar-Hhh’ Jhi=8.4
7. 7.77-7.80 2H doublet Ar-Hgg’ Jgf=8.7
8. 7.80-7.85 1H doublet CHz(vinylic) Jzy=15
9. 7.82-7.84 2H doublet Ar-Hii’ Jih=8.4
10. 7.87-7.92 1H doublet CHy(vinylic) Jyz=15
11. 8.34 1H singlet CHx
38




















IR SPECTRAL STUDY OF 1-ARYL-3-(1',N-PHENYL-3'-p-ETHOXYPHENYL-
PYRAZOL-4'-YL)-2-PROPEN-1-ONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.





































































































































































Sr. R Molecular Molecular M. P Rf* Yield % of Nitrogen
No. Formula Weight oC Value % Calcd. Found
1 2 3 4 5 6 7 8 9
1a C6H5- C26H22N2O2    394  124 0.54 62    7.10      7.05
1b 4-NH2-C6H4- C26H23N3O2 409 114 0.64 58             10.26         10.22
1c 4-Cl-C6H4- C26H21ClN2O2 428.5 168 0.58 78              6.53 6.49
1d 4-Br-C6H4- C26H21BrN2O2    473  168 0.42 65    5.92      5.87
1e 4-F-C6H4- C26H21FN2O2 412 211 0.53 56              6.79           6.73
1f 2-OH-C6H4- C26H22N2O3    410  124 0.68 67    6.82      6.78
1g 4-OH-C6H4- C26H22N2O3    410  195 0.47 73    6.82      6.77
1h 4-OCH3-C6H4- C27H24N2O3    424  204 0.49 68    6.60      6.54
1i 4-CH3-C6H4- C27H24N2O2    408  145 0.71 58    6.86      6.81
1j 4-NO2-C6H4- C26H21N3O4    439  154 0.58 68    9.56      9.53
1k 3-NO2-C6H4- C26H21N3O4    439  173 0.65 69    9.56      9.54
1l 2-C4H3S- C24H20N2O2S    400  146 0.49 52    6.99      6.95
TABLE-1 : PHYSICAL CONSTANTS OF 1-ARYL-3-(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-
1-ONES























B. coccus 10 19 18 13 16 20 18 12 17 18 13 16 25 18 20 22 0
S. aureus 21 17 16 15 18 15 17 21 16 17 21 14 25 19 15 21 0
E. aerogenes 14 16 17 12 20 13 16 18 13 14 19 21 20 21 22 19 0
P. aeruginosa 18 18 13 16 15 19 12 16 23 13 14 17 22 21 16 23 0
A. niger 17 15 18 17 20 18 14 14 17 19 15 15 0 0 0 0 26






















The antibacterial activity of chalcones (type-I) revealed that all the compounds
were able to inhibit the growth of Gram positive & Gram negative bacterial strains.
In case of Gram positive bacterial strain maximum activity was observed in
compound bearing R = 2-hydoxyphenyl and 4-bromophenyl against B. coccus. The
significant activity was displayed by compound having R=Phenyl, 4-chlorophenyl,4-anisyl
and 3-nitrophenyl against S. aureus.
In case of Gram negative bacterial strain all the compounds were least active
against Pseudomonas, except R= 4-hydroxyphenyl and 2-thiophene. The compounds
having R=4-chlorophenyl and 4-anisyl have shown good activity against Aerogenes.
ANTIFUNGAL ACTIVITY
All the compound exhibited mild activity against fungal strain A. niger except
compounds having R= 4-aminophenyl and 4-hydaroxyphenyl which showed good activity
against A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin,erythromycin & greseofulvin.
ANTITUBERCULAR ACTIVITY
The compounds having R = 4-bromophenyl,4-chlorophenyl,2-hydroxyphenyl and
4-anisyl have displayed percentage inhibition in the range of 98-90% and compounds
bearing R = 4-fluorophenyl and 4-tolyl showed percentage inhibition in the range of
60-40% against Mycobacterium tuberculosis H37 Rv.The antitubercular activity data
have been compared with standard drug rifampin.
44




SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazoline derivatives represent one of the most active class of compounds having
a wide spectrum of biological activities. Looking to the interesting properties of
pyrazolines it was considered worthwhile to synthesise a series of pyrazolines of type-
(II) for obtaining biologically potent agents which were prepared by reacting chalcones
of type (I) with phenylhydrazine in the presence of piperidine.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The










Type (II)       R = Aryl
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Type - (II) R = Aryl
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis  of  3-(p -Bromophenyl)-5-(1' ,N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-pyrazoline
 A mixture of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-
4'-yl)-2-propen-1-one (4.87 g, 0.01 M), hydrazine hydrate (1.08 g, 0.01 M)  in 25 ml
methanol was refluxed for 10 hrs. . The reaction mixture was poured on to crushed ice.
The product was isolated and crystallised from ethanol. Yield 68%, m.p. 123oC
(C26H23BrN4O; Required : C, 64.07; H, 4.76; N, 11.50;  Found : C, 64.02; H, 4.69;
N, 11.45%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 2.
(E) Antimicrobial  activity of  3-Aryl-5-(1' ,N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 2.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(p-TOLYL)-5-(1',N-PHENYL-3'-p-ETHOXYPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINE
 Observed
Alkane C-H str. (asym.) 2948 2975-2950 413
-CH3 C-H str. (sym.) 2879 2880-2860
C-H i.p.def. (asym.) 1436 1470-1435
C-H o.o.p. def. (sym.) 1398 1390-1370
Aromatic C-H  str. 3074 3080-3030 414
C=C str. 1583 1585-1480
C-H i.p. def. 1095 1125-1090
C-H o.o.p. def   812 835-810
Pyrazole C=N str. 1606 1630-1590 415
moiety C-N str. 1066 1230-1020
Ether C-O-C str. (asym.) 1245 1275-1200 413
C-O-C str. (sym.) 1028 1075-1030
Pyrazoline C=N str. 1583 1630-1590 417
(overlapped)
C-N str. 1172 1230-1020
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)







  of Protons
Multiplicity Inference J Value
In Hz
1. 1.40-1.44 3H triplet -OCH2CH3  JCH3 = 6.0
2. 3.01-3.09 1H double CHl Jlk = 15
doublet Jij = 6.0
3. 3.54-3.63 1H double CHk Jkl  = 15
doublet Jkj = 3.0
4. 3.98-4.04 2H quartret -OCH2CH3 JCH2 = 6.0
5. 5.82-5.87 1H double CHj Jjk = 12.0
doublet Jji  = 3.0
6. 6.89-6.91 2H doublet Ar-Hff’ Jfg  = 8.1
7. 7.21-7.26 1H triplet Ar-Hc
c
-
8. 7.37-7.40 2H triplet Ar-Hbd -
9. 7.50 4H multiplat Ar-HaeAr-Hii’ -
10. 7.60-7.63 2H doublet ArHgg’ Jgh = 8.1
11. 7.66-7.68 2H doublet ArHhh’ Jhi = 7.8































































































































































































































Sr. R Molecular Molecular M. P Rf* Yield % of Nitrogen
No. Formula Weight oC Value % Calcd. Found
1 2 3 4 5 6 7 8 9
TA B L E - 2 : P H Y S I C A L  C O N S T A N T S  O F  3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p- E T H O X Y P H E N Y L
P Y R A Z O L -4'-YL) PYRAZOLINES
*TLC Solvent System : Acetone : Benzene (1 :9)
2a C6H5- C26H24N4O 408 158 0.58 58 13.72 13.70
2b 4-NH2-C6H4- C26H25N5O 423 110 0.55 58 16.54 16.49
2c 4-Cl-C6H4- C26H23ClN4O 442.5 101 0.61 58 12.65 12.60
2d 4-Br-C6H4- C26H23BrN4O 487 123 0.56 68 11.50 11.45
2e 4-F-C6H4- C26H23FN4O 426 170 0.67 64 13.14 13.08
2f 2-OH-C6H4- C26H24N4O2 424 189 0.48 74 13.20 13.14
2g 4-OH-C6H4- C26H24N4O2 424 175 0.53 64 13.20 13.15
2h 4-OCH3-C6H4- C27H26N4O2 438 132 0.58 62 12.78 12.73
2i 4-CH3-C6H4- C27H26N4O 422 97 0.55 56 13.26 13.20
2j 3-NO2-C6H4- C26H23N5O3 453 146 0.64 64 15.44 15.40
2k 4-NO2-C6H4- C26H23N5O3 453 126 0.54 58 15.44 15.40























B. coccus 22 20 18 13 16 21 11 14 17 18 13 18 25 18 20 22 0
S. aureus 19 17 15 18 18 15 17 21 16 17 21 16 25 19 15 21 0
E. aerogenes 15 14 17 12 23 10 21 20 13 15 17 12 20 21 22 19 0
P. aeruginosa 17 18 14 24 15 19 12 16 23 13 14 17 22 21 16 23 0
A. niger 18 14 18 17 21 18 14 14 17 21 15 15 0 0 0 0 26
























It has been observed from the experimental data that all compounds of type
(II) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However, the maximum activity was observed in compounds bearing R=phenyl  and
2-hydroxyphenyl substituents against B.coccus. The significant activity was observed in
compounds bearing R=4-anisyl and 4-nitrophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=4-fluorophenyl
against E.aerogenes. In case of P.aeruginosa all the compounds were least active
except R=4-bromophenyl and 4-tolyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=fluorophenyl and 3-
nitrophenyl against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-5-
(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazoline derivatives represent one of the modest class of compounds  possessing
wide range of pharmacological activities.It was considered worthwhile to synthesise
some new pyrazolines bearing 1,N-phenyl-3-p-ethoxyphenyl-4-formyl pyrazole nucleus.
The preparation of 1,N-acetyl-3-aryl-5-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-
pyrazolines (III) have been under taken by cyclocondensation of chalcones of type (I)
with hydrazine hydrate in glacial acetic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological
assay  l ike  an t i tubercu la r  ac t iv i ty  towards  a  s t ra in  of  Mycobacter ium

















Type (III)       R = Aryl
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Type - (III) R = Aryl
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-5-
(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthes is  of  1 ,N-Acetyl -3- (p -bromophenyl) -5- (1 ' ,N-phenyl-3 ' -p-
ethoxyphenyl-pyrazol-4'-yl)-pyrazoline
 A mixture of 1-(p-bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-
4'-yl)-2-propen-1-one (4.73 g, 0.01 M) in 25 ml absolute alcohol,  hydrazine hydrate
(1 g, 0.02 M) and glacial acetic acid (10 ml) was refluxed for 8 hrs. The reaction mixture
was poured on to crushed ice. The product was isolated and crystallised from ethanol.
Yield 72%, m.p.93oC (C28H25BrN4O2; Required : C, 63.52; H, 4.76; N, 10.58;
Found : C, 63.46; H, 4.71; N, 10.54%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 3.
(E) Antimicrobial  act iv i ty  of  1 ,N-Acetyl-3-aryl-5-(1' ,N-phenyl-3' -p-
ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 3.
(F) Anttubercular act iv i ty  of  1 ,N-Acety l -3-aryl -5- (1 ' ,N-phenyl -3 ' -p-
ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
The antitubercular evaluation of the compounds was carried out as described in
[A] Part-I, section-I (D). The antitubercular activity data are showen in Table No. 3a.
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TABLE NO. 3a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR ACTIVITY
                                                                                              R = Aryl
TAACF, Southern Research Institute                      Dr. H. H. Parekh
Primary Assay Summary Report           Saurashtra University
 Sample Corp Where,R= Supplier Assay MTb MIC  % Activity
 ID ID Strain µg/ml Inhib
 295684 NV-18 4-NO2-C6H4 Sau.uni Alamar H37Rv >6.25 80 -
 295689 NV-23 4-CH3-C6H4 Sau. uni Alamar H37Rv >6.25 37 -
 295680 NV-14 2-C4H3S- Sau.uni Alamar H37Rv >6.25 22 -
 295681 NV-15 4-Br-C6H4 Sau.uni Alamar H37Rv >6.25 15 -
 295679 NV-13 -C6H5 Sau.uni Alamar H37Rv >6.25 09 -
 295685 NV-19 2-OH-C6H4 Sau.uni Alamar H37Rv >6.25 09 -
 295686 NV-20 4-OH-C6H4 Sau.uni Alamar H37Rv >6.25 06 -
 295687 NV-21 3-NO2-C6H4 Sau.uni Alamar H37Rv >6.25 04 -
 295682 NV-16 4-F-C6H4 Sau.uni Alamar H37Rv >6.25 00 -
 295683 NV-17 4-NO2-C6H4 Sau.uni Alamar H37Rv >6.2 00 -
 295688 NV-22 4-NH2-C6H4 Sau.uni Alamar H37Rv >6.25 00 -
 295690 NV-24 4-OCH3-C6H4 Sau.uni Alamar H37Rv >6.25 00 -
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-ACETYL-3-(p-CHLOROPHENYL)-5-(1',N-
PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 413
-CH3 C-H str. (sym.) 2852 2880-2860
C-H i.p.def. (asym.) 1415 1480-1435
C-H o.o.p. def. (sym.) 1361 1390-1370
Aromatic C-H  str. 3060 3080-3030 414
C=C str. 1554 1585-1480
C-H i.p. def. 1101 1125-1090
C-H o.o.p. def   827 835-810
Pyrazole C=N str. 1596 1630-1590 415
moiety C-N str. 1101 1230-1020
                     (overlapped)
Ether C-O-C str. (asym.) 1247 1275-1200 413
C-O-C str. (sym.) 1058 1075-1020
Pyrazoline C=O str. 1670 1660-1600 417
C=N str. 1596 1630-1590
C-N str. 1247 1230-1020
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
























1. 1.39-1.44 3H triplet -OCH2CH3 JCH3 = 6.9
2. 2.43 3H singlet -COCH3                     -
3. 3.00-3.07 1H double CHl Jlk =  17.4,
doublet Jlj = 4.5
4. 3.60-3.15 1H double CHk Jkl = 17.4
doublet Jkj = 11.7
5. 4.04-3.96 2H quartret -OCH2CH3 JCH2 = 7.0
6. 5.88-5.83 1H double CHj Jjk = 11.6
doublet Jjl = 4.4
7. 6.91-6.88 1H doublet Ar-Hff’ Jfg = 8.4
8. 7.25-7.21 1H triplet Ar-Hc                     -
9. 7.42-7.37 2H triplet Ar-Hbd                     -
10. 7.63-7.60 2H doublet Ar-Hgg’ Jgf = 8.4
11. 7.49-7.46 4H mulitplat Ar-Hae,Ar-Hhh’
12. 7.68-7.65 2H doublet Ar-Hii’ Jij = 8.0
13. 7.77 1H singlet CHx       -
60



























IR SPECTRAL STUDY OF  1,N-ACETYL-3-ARYL-5-(1',N-PHENYL-3'-p-
ETHOXYPHENYL-PYRAZOL-4'-YL)PYRAZOLINES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R C=O str.

























































































































































































































TABLE-3 : PHYSICAL CONSTANTS OF 1,N-ACETYL-3-ARYL-5-(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-
4'-YL)PYRAZOLINES
    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                  8      9
3a C6H5- C28H26N4O2    450  168 0.68 59    12.44      12.41
3b 4-NH2-C6H4- C28H27N5O2 465 121 0.64 60 15.04 15.01
3c 4-Cl-C6H4- C28H25ClN4O2 484.5  87 0.57 70 11.55 11.49
3d 4-Br-C6H4- C28H25BrN4O2    529   93 0.60 72    10.58      10.54
3e 4-F-C6H4- C28H25FN4O2 468 201 0.68 64 11.96 11.91
3f 2-OH-C6H4- C28H26N4O3    466  185 0.49 58    12.01         11.96
3g 4-OH-C6H4- C28H26N4O3    466  123 0.55 54    12.01         11.97
3h 4-OCH3-C6H4- C29H28N4O3    480   99 0.65 76    11.66         11.61
3i 4-CH3-C6H4- C29H28N4O2    464  154 0.53 51    12.06      12.02
3j 3-NO2-C6H4- C28H25N5O4    495  111 0.49 74    14.13      14.09
3k 4-NO2-C6H4- C28H25N5O4    495   95 0.58 68    14.13      14.07
3l 2-C4H3S- C26H24N4O2S    456  183 0.62 61    12.27      12.22























B. coccus 20 17 14 18 15 16 19 19 23 15 16 18 25 18 20 22 0
S. aureus 17 18 13 16 15 19 16 21 17 13 16 16 25 19 15 21 0
Aerogenes 15 16 15 17 23 14 16 15 17 23 18 12 20 21 22 19 0
Pseudomonas 19 20 12 18 17 16 19 21 19 18 12 17 22 21 16 23 0
A. niger 18 16 15 16 17 15 20 21 18 19 15 15 0 0 0 0 26
























From the experimental data, it has been observed that the compound bearing
R=4-tolyl have displayed significant activity against B.coccus. The compound bearing
R=4-anisyl have shown good activity against S. aureus.
In case of Gram negative bacterial strains, the compounds with R=4-fluorophenyl
and 3-nitrophenyl have shown considerable activity against Aerogenes. The maximum
activity was displayed by the compounds bearing R=4-anisyl against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-anisyl have displayed highest activity
against A.niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin,erythromycin & greseofulvin.
ANTITUBERCULAR ACTIVITY
All the compounds of type (III) were found to be less active against
Mycobacterium tuberculosis H37Rv.
The antitubercular activity data have been compared with standard drug rifampin.
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Pyrimidine is the most important member of all diazines as this ring system occurs
widely in living organism. Several analogues of nucleic acid have been used as a compound
that interfere with the synthesis and function of nucleic acid,an example is fluorouracil
which has been used in cancer treatment.
Pyrimidine derivatives like uracil(I), thymine(II) and cytosine(III) occur widely
in nature showing remarkable pharmaceutical importance. Pyrimidine and its derivatives
have gained prominence because of their potential pharmaceutical values. Many
pyrimidine derivatives play a vital role in many physicological action, some of the building
blocks of DNA and RNA.
Pyrimidine is considered to be a resonance hybrid of charged and uncharged
cannonical structures, its resonance energy has been found to be more than benzene or
pyridine. The naturally occuring pyrimidine derivative was first isolated by Grabial and
Colman in 1870, and its structure was confirmed in 1953 as 5-b-gluco-pyranoside of
divicine.
SYNTHETIC ASPECTS
Different methods for the synthesis of pyrimidinones have been cited in the
literature.113
1. Biginelli114 investigated that condensation of aromatic aldehyde with b-ketoester
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2. Hussain Ali Saleiman  et.al.115  have prepared oxopyrimidine derivatives(VII) by
using urea in alcoholic KOH.
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Pyrimidine derivatives have been proved to be of great importance in exhibiting
and enhancing the biological activities such as,
(a) Antitumor117
(b) Carcinostatic118










Baraldi P. G. et. al.133 have discovered triazolo [1,5-c] pyrimidine derivatives
as a new class of A2A adenosine receptor antagonists.Azaryan et. al.
134 have synthesised
pyrimidine diones as antitumor agent. Krivongov and co-workers135 have synthesised
pyrimidinone derivatives possessing immunotropic and antiinflammatory activity. Timothy
and co-workers136 have suggested imidazolyl pyrimidinones as antiviral.Balis F. M. et.
al.137 has investigated pyrimidines (X) used in the treatment of leukamia in childhood.
Amuti Kofies et. al.138 have suggested pyrimidinones as herbicidal and
plant growth regulators. K. Mogilaiah et. al.139 have prepared spiropyrimidinones as
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as potent antimicrobial and antitumor agent.Bruce M. A & co-workers141 have pre-
pared the dihydro pyrimidinones as NPY antagonist.Antitumor activity of new
pyrimidinone of sesquiterpene lactones has been found by Angelina Quintero et. al.142
Barbuliene M. M. et. al.143 have synthesised pyrimidinones as antiinflammatory agent.
El-Agrody A. M. et.al.144 have studied antimirobial activity of pyrimidine
derivatives.Patricia F. F. et. al.145 have synthesised and screened for their leukocyte
functions inhibitor activity. Dumas Jacques et. al.146 have synthesised pyrimidinones
and tested their hyperproliferative disorder activity.Tsann-Long Su et. al.147 have
reported pyrimidines (XI) as antitumor agents.
Richard J. Perneu et. al.148 have discovered pyrimidine derivatives (XII) as
adenosine kinase inhibitors. Sharad Verma et. al.149 have prepared pyrimidines (XIII)








R1 = NH2, OH
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Viney Hather & A. K. Madan150 have prepared pyrimidinones(XIV) as anti-
HIV agents.Aleem Gangiee & co-workers151 have prepared pyrimidinone derivatives
(XV) as non classical antitolate inhibitors of thymidylate synthase.
Recently, Antonello Mai et. al.152 have synthesised pyrimidine derivative (XVI)
as non-nucleoside reverse transcriptase inhibitors.Maria T. Cocco and co-workers153
have synthesised hydrazinopyrimidine-5-carbonitrile derivatives and reported their
antitumor activity.Rudolf Waelchli et. al.154 have synthesised pyrimidine derivatives as
IKK inhibitors. Naveen Chandra and co-workers155 have synthesised some aryl
substituted terpenyl pyrimidines and reported their antileishmanial activity.
Literature survey reveals that pyrimidine derivatives possess potential drug activity.
Looking to the diversified biological activity, it appeared of interest to synthesize some
pyrimidines bearing pyrazole moiety, in order to achieving compounds having better



























R = R1 = H, Me
X = Alkyl / Aryl
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ECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2
A RY L I M I N O - 3 , N - A R Y L - 5 - [ 1 , ' N - P H E N Y L - 3 ’ - P
ETHOXYPHENYL)-4'-PYRAZOLYL-METHINO]-4
THIAZOLIDINONES
SECTON- II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-
ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-P-
E T H O X Y P H E N Y L - P Y R A Z O L - 4 ' - Y L ] - 1 , 2 , 3 , 4 -
TETRAHYDROTHIAZOLIDINO-[4,5-e]-PYRIMIDINES
SECTON- II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-
ARYLIMINO-7,N-ARYL-2-THIO-4-[1',N-PHENYL-3'-P-
E T H O X Y P H E N Y - P Y R A Z O L - 4 ' - Y L ] - 1 , 2 , 3 , 4 -
TETRAHYDROTHIAZOLIDINO-[4,5-e]-PYRIMIDINES
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-4'-PYRAZOLYL METHINO]-
4-THIAZOLIDINONES
Recently much interest has been foucused on the synthesis and biodynamic
activities of arylidene and it is a good synthon for various heterocyclic rings. With a view
to obtaining compounds having better therapeutic activities, we have synthesised 2-
arylimino-3-N-aryl-5-[1',N-phenyl-3'-(p-ethoxyphenyl)-4'-pyrazol methino]-4-
thiazolidinones by the condensation of pyrazole aldehyde with various thiazolidinone
derivatives.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of synthesised compounds were compared with standard drugs.



























































2.NH2 R + CS2
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-ARYL-
5-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-4'-PYRAZOLYL METHINO]-4-
THIAZOLIDINONES
[A] Preparation of N1, N3-Bis-p-anisyl thiourea156
In a round bottom flask, a mixture of p-fluroaniline(0.2M), carbon disulphide (7ml,
0.01M) and absolute alcohol was heated  for 5-6 hrs. at temp 40oC. On completion of
reaction, the excess of carbon disulphide and alcohol was removed by distillation. The
product was treated with hydrochloric acid to remove excess of amine present and
crude product was isolated and crystallised from ethanol. m.p.203 oC.
[B] Preparat ion of  2-p -Fluorophenyl imino-3-p - f luoroani l ine-5H-4
thiazolidinones157
A solution of N1, N3-bis-p-fluroaniline thiourea (0.01M) and chloroacetic acid
(0.94g, 0.01M) in glacial acetic acid (15 ml) was refluxed with fused sodium acetate
(1.25g, 0.015M) for 8 hrs. The reaction product was poured in water, kept overnight,
crude product was isolated and crystallised from ethanol. m.p. 209oC.
[C] Preparation of 2-(p-Fluorophenylimino)-3.N-(p-flurophenyl)-5-[1',N-
phenyl-3'-(p-ethoxyphenyl)-4'-pyrazolyl methino]-4-thiazolidinone
A mixture of 2-(p-fluroanilineimino)-3-p-fluroaniline-5H-4-thiazolidinone (3.36g,
0.01M) 1,N-phenyl-3-(p-ethoxyphenyl)-4-formyl pyrazole (2.92g, 0.01M) and fused
sodium acetate (1.25g, 0.015M) was refluxed in glacial acetic acid (15 ml) for 9-10
hrs. at temp 120oC. cooled, poured into water and treated with ammonia to remove
excess of glacial acetic acid. The product was isolated and crystallised from ethanol.
yield 72% m.p. 186oC (C33H24F2N4O2S : Found : C, 68.50%; H, 4.18%; N, 9.68%
Requires : C, 68.44%; H, 4.12%; N, 9.63%).
TLC solvent system : Acetone : Benzene (2 : 8).
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Similarly other substituted thiazolidinones have been prepared. The physical data
are recorded in Table No. 4.
[D] Therapeutic activity of 2-Arylimino-3,N-aryl-5-[1',N-phenyl-3'-(p-
ethoxyphenyl)-4'-pyrazolylmethino]-4-thiazolidinones
Antimicrobial testing was carried out as described in [a] Part-I, Section-I (D). The
zone of inhibition of the test solution are recorded in Graphical Chart No.4.
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IR SPECTRAL STUDY OF 2-(p -FLUOROPHENYLIMINO)-3 ,N-(p -
FLUOROPHENYL)-5- [ 1 ’ , N - P H E N Y L - 3 ’ - ( p - E T H O X Y P H E N Y L ) -
4’PYRAZOLYLMETHINO]-4-THIAZOLIDINONE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.) ObservedAlkane C-H str. (asy.) 2962 2975-2950 413-CH3  t. 854 8086- i.pdef (asy.) 14147-1435Aromtic CH str. 3039 3080=C t. 158 15-148 414- i.p def. 05 209CH o..   823 835-81Pyrazole =N str. 16160590 41moiety - t.8 23-12C-F 79 80560Ether -O- str. (asym.) 1265 127-12 413 t. 0050ThiazolidinoeC= str. 176 176-165 419rig N t. 63 5090-S str. 648 7-6
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1. 1.42-1.46 3H triplet -OCH2CH3 JCH3=6.81
2. 3.84-3.82 6H singlet -OCH3 -
3. 4.05-4.11 2H quartet -OCH2CH3 JCH2=7.0
4. 6.92-6.98 4H multiplet Ar-Hhh’,Ar-Hgg’ -
5. 6.98-7.01 2H doublet Ar-Hii’ Jih=8.7
6. 7.02-7.04 2H doublet Ar-Hkk’ Jkj=8.7
7. 7.36-7.38 3H multiplet Ar-Ha,c,e -
8. 7.46-7.50 2H triplet  Ar-Hbd -
9. 7.58-7.60 2H double Ar-Hjj’ Jjk=8.7
  10. 7.74-7.76 2H double Ar-Hff’ Jfg=8.2
  11. 7.84 1H singlet CHy -
  12. 8.08 1H singlet CHx -
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 2-(p-ANISYLIMINO)-3,N-(p-ANISYL)-5-[1 ’ ,N-



































    (d ppm)
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      4a C6H5- 1708
4b 4-OCH3-C6H4- 1709











IR SPECTRAL STUDY OF 2-ARYLIMINO-3,N-ARYL-5-[1',N-PHENYL-
3'-(p-ETHOXYPHENYL)-4'-PYRAZOLYL METHINO]-4-THIAZOLIDINONES
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*TLC Solvent System :  Acetone: Benzene (2 : 8)
TABLE-4 : PHYSICAL CONSTANTS OF 2-ARYLIMINO-3,N-ARYL-5-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-4'-
PYRAZOLYL METHINO]-4-THIAZOLIDINONES
4a C6H5- C33H26N4O2S 542 174 0.59 68 10.32 10.28
4b 4-OCH3-C6H4- C35H30N4O4S 602 158 0.61 59 9.30 9.26
   4c 3-OCH3-C6H4- C35H30N4O4S 602 205 0.62 71 9.30 9.25
4d 4-CH3-C6H4- C35H30N4O2S 570 145 0.58 68 9.82 9.78
4e 3-CH3-C6H4- C35H30N4O2S 570 202 0.64 58 9.82 9.78
4f 4-OH-C6H4- C33H26N4O4S 574 147 0.52 71 9.75 9.70
4g 4-F-C6H4- C33H24F2N4O2S 578 186 0.58 72 9.68 9.63
4h 4-Cl-C6H4- C33H24Cl2N4O2S 611 139 0.68 69 9.16 9.13
4i 4-Br-C6H4- C33H24Br2N4O2S 700 229 0.64 55 8.00 7.97
4j 3,4-(Cl)2-C6H3- C33H22Cl4N4O2S 680 201 0.53 61 8.23 8.19
4k 4-NO2-C6H4- C33H24N6O6S 632 210 0.55 68 13.28 13.25
4l 3-NO2-C6H4- C33H24N6O6S 632 299 0.57 76 13.28 13.24
 Sr. R Molecular Molecular M. P Rf* Yield % of Nitrogen
 No. Formula Weight oC Value % Calcd. Found























B. coccus 17 22 15 19 21 13 19 12 12 16 14 17 25 18 20 22 0
S. aureus 14 12 21 10 14 18 15 16 22 26 21 19 25 19 15 21 0
E. aerogenes 25 17 15 18 16 21 10 12 16 17 14 21 20 21 22 19 0
P. aeruginosa 13 18 14 21 20 18 12 15 12 21 15 14 22 21 16 23 0
A. niger 17 21 15 18 19 17 18 18 13 17 22 17 0 0 0 0 26






















It has been concluded from the experimental data that the compounds bearing
R=4-anisyl and 3-tolyl have displayed good activity against B.coccus. The compounds
bearing R=3-anisyl,4-bromophenyl, 3,4-dichlorophenyl and 4-nitrophenyl have shown
considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E.aerogenes except the compound bearing R=phenyl,3-nitrophenyl and 4-
hydroxyphenyl. While the compounds bearing R=4-tolyl, 3,4-dichlorophenyl showed
significant activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=4-anisyl and 4-nitrophenyl  displayed highest activity
against A.niger.
The ant ibac ter ia l  ac t iv i ty  was  compared  wi th  s tandard  drug
viz.amoxicillin,benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity
was compared with standard drug viz. greseofulvin.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-ARYL-2-OXO-
4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)PYRAZOL-4'-YL],1,2,3,4-TETRAHYDRO
THIAZOLIDINO-[4,5-e]-PYRIMIDINES
Many pyrimidinone derivatives are associated with diversified biological
properties. It was thought of interest that a pyrimidinone ring couple to pyrazole nucleus
and thiazolidinone nucleus, the resulting compounds may possess significant biological
potency.Pyrimidinones of type (V) have been prepared by the condensation of 2-
arylimino-3-aryl-5H-4-thiazolidinone, 1,N-phenyl-3-(p-ethoxyphenyl)-4-formyl-
pyrazole and urea in glacial acetic acid with fused sodium acetate.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological




























R = ArylType - (V)
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-ARYL-
2-OXO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-PYRAZOL-4'-YL]-1,2,3,4-
TETRAHYDRO-THIAZOLIDINO-[4,5-e]-PYRIMIDINES
[A] Prepara t ion  o f  2 -p -F luoropheny l imino-3 - p - f luoropheny l -5H-4 -
thiazolidinone157
See, Part-II, Section-I (B)
[B] Preparation of 6-(p-Fluorophenylimino)-7,N-(p-fluoropheny)-2-oxo-4-(1',N-
phenyl-3'-(p-ethoxyphenyl-pyrazol-4'-yl)-1,2,3,4 tetrahydro thiazolidino-
[4,5-e]-pyrimidine
A mixture of 2-p-fluorophenylimino-3-(p-fluorophenyl)-5H-4-thiazolidinone
(3.36g, 0.01M), 1,N-phenyl-3-(p-ethoxyphenyl)-4-formyl-pyrazole (2.92g, 0.01M)and
urea (0.60g, 0.01M) were mixed in glacial acetic acid (20 ml) with fused sodium
acetate(1.25gm, 0.015M). The reaction mixture was refluxed for 10 hrs. cooled, poured
into crushed ice. The product was isolated and crystallised from methanol-DMF. Yield
72%, m.p. 232oC (C34H26F2N6O2S, Found : C, 65.99%; H, 4.22%; N, 13.54%
Requires : C, 65.94%; H,4.17%; N, 13.48%;).
TLC solvent system : Ethyl acetate : Hexane (1.8 : 8.2).
Similarly other pyrimidines were prepared. The physical data are recorded in Table
No. 5.
[C] Therapeutical activity of 6-Arylimino-7,N-aryl-2-oxo-4-[1',N-phenyl-3'-(p-
ethoxyphenyl)-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-(4,5-e)-
pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The zone
of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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IR SPECTRAL STUDY OF 6-p -FLUOROPHENYLIMINO-7,N-p -
FLUOROPHENYL-2-OXO-4-(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-
4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-d]-PYRIMIDINE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Observed
Alkane C-H str. (asym.) 2958 2975-2950 413
-CH3 C-H str. (sym.) 2844 2880-2860
C-H i.p.def. (asym.) 1415 1470-1435
Aromatic C-H str. 3082 3080-3030
C=C str. 1539 1585-1480 414
C-H i.p. def. 1151 1125-1090
C-H o.o.p. def 831 835-810
Pyrazole C=N str. 1616 1630-1590 415
moiety C-N str. 1224 1230-1020
C-F str. 758 830-560 413
Ether C-O-C str. (asym.) 1249 1275-1200 413
C-O-C str. (sym.) 1028 1075-1020
Pyrimidine C=O str. 1708 1750-1600 416
     ring N-H str. 3396 3500-3350
C=N str. 1627 1650-1550
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)































1. 1.25-1.47 3H triplet -OCH2CH3 JCH3=6.81
2. 4.08-4.11 2H quartret -OCH2CH3 JCH2=6.92
3. 6.95-6.97 2H doublet Ar-Hhh’ Jhi=8.7
4. 6.99-6.01 2H doublet Ar-Hgg’ Jgf=8.6
5. 7.05-7.08 2H doublet Ar-Hjj’ Jjk=8.5
6. 7.22-7.24 2H doublet Ar-Hii’ Jih=8.5
7. 7.33-7.38 2H triplet Ar-Hbd -
8. 7.42-7.52 3H multiplet  Ar-Ha,c,e -
9. 7.57-7.60 2H doublet Ar-Hff ’ Jfg=8.5
  10. 7.76-7.73 2H doublet Ar-Hkk’ Jkj=8.7
  11. 7.87 1H singlet CHy -




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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IR SPECTRAL STUDY OF  6-ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-


































































































































































































    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
*TLC Solvent System :Ethylacetate : Hexane (1.8 : 8.2)
TABLE-5 : PHYSICAL CONSTANTS OF 6-ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)
PYRAZOL-4'-YL],1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-e]-PYRIMIDINES
5a C6H5- C34H28N6O2S    584  125 0.58 66    14.37      14.32
5b 4-OCH3-C6H4- C36H32N6O4S    644  144 0.66 61    13.03      12.98
   5c 3-OCH3-C6H4- C36H32N6O4S    644  235 0.67 62    13.03      12.97
5d 4-CH3-C6H4- C36H32N6O2S    612  145 0.71 71    13.72      13.68
5e 3-CH3-C6H4- C36H32N6O2S 612 202 0.64 54 13.72 13.68
5f 4-OH-C6H4- C34H28N6O4S    616  105 0.50 69    13.63      13.58
5g 4-F-C6H4- C34H26F2N6O2S    620  232 0.57 72    13.54      13.48
5h 4-Cl-C6H4- C34H26Cl2N6O2S    653  136 0.62 59    12.86      12.80
5i 4-Br-C6H4- C34H26Br2N6O2S    742  149 0.64 54    11.32      11.27
5j 3,4-(Cl)2-C6H3- C34H24Cl4N6O2S    722  185 0.56 61    11.63      11.28
5k 4-NO2-C6H4- C34H26N8O6S    674  210 0.55 67    16.61      16.57























B. coccus 20 15 15 17 19 16 22 17 16 16 20 13 25 18 20 22 0
S. aureus 15 17 13 15 16 17 20 22 21 19 18 23 25 19 15 21 0
E. aerogenes 14 24 18 17 13 20 18 14 15 13 15 17 20 21 22 19 0
P. aeruginosa 22 18 21 18 14 23 12 18 14 17 22 20 22 21 16 23 0
A. niger 11 23 19 12 18 15 19 22 17 21 18 19 0 0 0 0 26













GRAPHICAL CHART NO. 5 : ANTIMICROBIAL ACTIVITY OF 6-ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-









It has been concluded from the experimental data that the compounds bearing
R= 4-fluorophenyl have displayed good activity against B.coccus. The compounds
bearing R= 4-chlorophenyl, 4-bromophenyl and 3-nitrophenyl have show considerable
activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E.aerogenes except the compound bearing R=4-anisyl. While the compounds bearing
R=phenyl, 3-anisyl,4-hydroxyphenyl and 4-nitrophenyl showed significant activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=4-anisyl,3,4-dichlorophenyl and 4-chlorophenyl
displayed highest activity against A.niger.
The ant ibac ter ia l  ac t iv i ty  was  compared  wi th  s tandard  drug
viz.amoxicillin,benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity
was compared with standard drug viz. greseofulvin.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-THIO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL) PYRAZOL-4'-
YL],1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-e]-PYRIMIDINES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. It was considered worthwhile to synthesise
thiopyrimidines of type (VI), which have been prepared by the condensation of 2-
arylimino-3-aryl-5H-4-thiazolidinone, 1,N-phenyl-3-(p-ethoxyphenyl)-4-formyl-
pyrazole and thiourea in glacial acetic acid with fused sodium acetate.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological


























R = ArylType - (VI)
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-THIO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-PYRAZOL-4'-YL]-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-e]-PYRIMIDINES
[A] Preparation of 2-p-Fluorophenylimino-3-(p-fluorophenyl)-5H-4-
thiazolidinone157
See, Part-II, Section-I (B)
[B] Preparation of 6-(p-Fluorophenylimino)-7,N-(p-fluoropheny)-2-thio-4-
(1' ,N-phenyl-3'-(p -ethoxyphenyl-pyrazol-4'-yl)-1,2,3,4tetrahydro
thiazolidino-[4,5-e]-pyrimidine
A mixture of 2-p-fluorophenylimino-3-(p-fluorophenyl)-5H-4-thiazolidinone
(3.36g, 0.01M) 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl-pyrazole (2.92g, 0.01M)
and thiourea (0.76g, 0.01M) were mixed in glacial acetic acid (20 ml) with fused sodium
acetate(1.25g, 0.015M). The reaction mixture was refluxed for 12 hrs. cooled and poured
into crushed ice. The product was isolated and crystallised from methanol-DMF. Yield
52%, m.p. 148oC (C34H26F2N6OS2, Found : C, 64.13`%; H, 4.12%; N, 13.24%
Requires : C, 64.08%; H, 4.08%; N, 13.20%;).
TLC solvent system : Acetone : Benzene (2.5 : 7.5).
Similarly other pyrimidines were prepared. The physical data are recorded in
Table No. 6.
[C] Therapeutical activity of 6-Arylimino-7,N-aryl-2-thio-4-[1',N-phenyl-3'-(p-
ethoxyphenyl)-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-(4,5-e)-
pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I(D). The
zone of inhibition of the test solution are recorded in Graphical Chart No.6.
7
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IR SPECTRAL STUDY OF  6-p -CHLOROPHENYLIMINO-7,N-p -
CHLOROPHENYL-2-THIO-4-(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-
4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-d]-PYRIMIDINE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Observed
Alkane C-H str. (asym.) 2923 2975-2950 413
-CH3 C-H str. (sym.) 2852 2880-2860
C-H i.p.def. (asym.) 1440 1470-1435
Aromatic C-H str. 3058 3080-3030
C=C str. 1598 1585-1480 414
C-H i.p. def. 1107 1125-1090
C-H o.o.p. def 831 835-810
Pyrazole C=N str. 1631 1630-1590 415
moiety C-N str. 1168 1230-1020
C-Cl str. 688 800-600 413
C-S-C str. (sym.) 1026 1075-1020
Pyrimidine N-H str. 3435 3500-3350 416
     ring C=N str. 1631 1650-1550
(overlapped)
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)

































1. 1.43-1.46 3H triplet -OCH2CH3 JCH3=6.81
2. 4.06-4.11 2H quartret -OCH2CH3 JCH2=6.92
3. 6.93-6.97 2H doublet Ar-Hhh’ Jhi=8.4
4. 6.99-7.01 2H doublet Ar-Hgg’ Jgf=8.4
5. 7.06-7.10 2H doublet Ar-Hjj’ Jjk=8.6
6. 7.22-7.24 2H doublet Ar-Hii’ Jih=8.3
7. 7.36-7.38 1H triplet Ar-Hc -
8. 7.44-7.51 4H multiplet Ar-Ha,b,d,e -
9. 7.58-7.60 2H doublet Ar-Hff ’  Jfg=8.4
  10. 7.74-7.76 2H doublet Ar-Hkk’ Jkj=8.6
  11. 7.87 1H singlet CHy -




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
9


















































































































































































    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
*TLC Solvent System : Acetone : Benzene (2.5 : 7.5)
TABLE-6 : PHYSICAL CONSTANTS OF 6-ARYLIMINO-7,N-ARYL-2-THIO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)
PYRAZOL-4'-YL],1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-e]-PYRIMIDINES
6a C6H5- C34H28N6OS2    600  169 0.59 71    14.64      14.59
6b 4-OCH3-C6H4- C36H32N6O3S2    660  159 0.59 69    12.76      12.69
6c 3-OCH3-C6H4- C36H32N6O3S2    660  148 0.57 58    12.76      12.71
6d 4-CH3-C6H4- C36H32N6OS2    628  215 0.68 69    13.41      13.35
6e 3-CH3-C6H4- C36H32N6OS2 628 108 0.64 58 13.41 13.36
6f 4-OH-C6H4- C34H28N6O3S2    632  268 0.50 70    13.32      13.27
6g 4-F-C6H4- C34H26F2N6OS2    636  148 0.57 52    13.24      13.20
6h 4-Cl-C6H4- C34H26Cl2N6OS2    669  198 0.62 63    12.59      12.53
6i 4-Br-C6H4- C34H26Br2N6OS2    758  128 0.67 58    11.11      11.09
6j 3,4-(Cl)2-C6H3- C34H24Cl4N6OS2    738  176 0.56 69    11.41      11.38
6k 4-NO2-C6H4- C34H26N8O5S2    690  164 0.59 71    16.27      16.19
























B. coccus 13 17 22 12 19 18 14 16 20 13 17 19 25 18 20 22 0
S. aureus 20 14 20 16 18 15 21 11 19 11 15 21 25 19 15 21 0
E. aerogenes 12 21 12 19 15 11 22 19 19 18 16 16 20 21 22 19 0
P. aeruginosa 15 24 18 15 20 16 13 17 10 18 22 19 22 21 16 23 0
A. niger 12 14 8 21 24 15 18 14 13 17 19 17 0 0 0 0 26













GRAPHICAL CHART NO. 6 : ANTIMICROBIAL ACTIVITY OF 6-ARYLIMINO-7,N-ARYL-2-THIO-4-[1',N-PHENYL-










It has been concluded from the experimental data that the compounds bearing
R=3-anisyl have displayed good activity against B.coccus. The compounds bearing
R= 4-fluorophenyl and 3-nitrophenyl have shown considerable activity against S.aureus.
In case of Gram negative bacterial strains, all the compounds were inactive against
E.aerogenes except the compound bearing R=4-anisyl and 4-fluorophenyl. While the
compounds bearing R=4-anisyl  and 4-nitrophenyl  showed significant activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=4-tolyl and  3-tolyl displayed highest activity against
A.niger.
The ant ibac ter ia l  ac t iv i ty  was  compared  wi th  s tandard  drug
viz.amoxicillin,benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity
was compared with standard drug viz. greseofulvin.
1 4
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Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activities.Azomethines are also
known as Schiff bases and they are well known intermediate for  the preparation
of azetidinones, thiazolidinones ,formazan,aryl acetamide and many other entities
of pharmaceutical potential. These are the compounds containing characteristic
-HC=N- group
Azomethines  are imino compounds which are formed by the reaction of primary
amine with aldehydes or ketones.When  one or both of  reactants  is aromatic, the imine
is stable. In case of aliphatic reactants the imines tend to decompose or polymerized.
SYNTHETIC ASPECTS
1. Recently , Rosallen J Anderson et al.158 have discovered new method for
synthesis of azomethine derivatives with the use of chlorominium salt.
2 . Imine formation involves two steps.159
(a) Addition of the amine to the carbonyl group of the aldehyde yields aldol .The
aldol  is rarely  capable of isolation.
(b) The loss of water to give an imine (azomethine). T h i s  corresponds to the
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3. Schiff base have been synthesised by the reaction of aldehyde with amine.160
THERAPEUTIC IMPORTANCE
Azomethine derivatives are excellent bioactive substances in pharmaceutical
industry. Inthe past years, the literature is enriched with progressive findings about the











Jerpan Krungkrai and co-workers170  have synthesised azomethine derivatives(V)
which showes antimalarial actvity. The malarial parasite Plasmodium falciparum
encodes for an a-cabonic anhydrase (CA) enzyme possessing catalytic properties distinct
of that of the human host and the synthesised compounds inhibiting a critical enzyme for
the  life cycle of the parasite.
R H
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Popesal et.al.171 suggested some schiff bases useful as carbonic anhydrase
inhibitors. Ergenc et.al.172 have synthesised azomethine derivatives (VI) showing
antifungal activity.
Afaf  H .and co-workers173 have prepared azomethines (VII ) possessing
potential antimicrobial activity. Wang Y. et al.174 have screened azomethines having
good plant hormone activity. Nadine Azas et al.175 have documented azomethine
derivative and screened for their antiparasitic activity against plasmodium falciparum,
Trichomonas faginalis and compared their toxicity versus human cell. Jayendra Patole
et al.176 have prepared some Schiff bases and evaluated them as  antitubercular agent.
J.M. Monti et al.177 have reported azomethines useful as H3-antaganist. S.Guniz
Kucukguzel et al.178 have screened azomethine derivatives for  their  anticonvulsant
activity. Huseyin Unver et al.179 have investigated azomethines and  studied their
antimicrobial activity. Neslihan and Reyhan180 have synthesized  a series  of new
azomethines (VIII ) and tested them as antitumer agent. R.S.Varma181 has synthesized
a series of new azomethines (IX) and evaluated them for antileishmanial activity.
Christos A. et al.182 have discovered several coumarin containing azomethine
derivatives and tested in vivo for their anti-inflammatory activity and in vitro for their
antioxidant  ability. Ilkay Kucukguzel and co-workers183 have synthesised Schiff bases
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anticonvulsant activity.  Perumal Panneerseivamhave184 discovered novel series of schiftf
base of 4-(4-aminophenyl) morpholine and evaluated them as antimicrobial agent.
Hojatollah M. et al.185 have reported azomethines useful as anticonvulsant agent. Sham
M.Sondhi et al.186 have documented azomethine derivatives( X) & evaluated them for
anti-inflammatory ,analgesic and kinase CDK-1, CDK-5, and GSK-3 inhibition activity.
Zhanyong  Guo and co-workers187 have discovered the azomethine derivatives
and reported their antifungal and antioxident activity. Most of the compounds showed
better inhibitory effect against Fusarium oxyporium , Vasinfectum , Alternaria Solani
and Valsa mali. Alladdin et al.188 have prepared schiff bases by combining 2,4
disubstituted thiazole and cyclobutane ring (XI) and studied their antibacterial properties
against C. tropicalis and Bacillus subtilis.
Jayendra Patole et al.189 reported novel schiff bases of p-aminosalicylic acid
containing hydroxy  rich  side chains which enhanced antimycobacterial activity against
Mycobacterium Smegmatis  and Mycobacterium bovis BCG. Dharmarajan Shriram et al.190
have synthesised azomethine derivatives and reported them as anti  HIV agent.
In view of therapeutic activities of azomethines , it was contemplated to synthesise
azomethine derivatives in search of agent possessing higher biological activity with least
side effects , which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF N-
ARYL-1,N-PHENYL-3-(p-ETHOXYPHENYL)-PYRAZOL-4-
AZOMETHINES








R1 = H, COOH, NO2















SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-1,N-PHENYL-3-
(p-ETHOXYPHENYL)-PYRAZOL-4-YL-AZOMETHINES
Azomethine derivatives are well known for their pharmacological activities.
Azomethines are also found as intermediate in organic synthesis. These findings
encouraged us to synthesise some new azomethines of type (VII) bearing pyrazole
nucleus. The synthesis was carried out by the condensation of 1,N-phenyl-3-
(p-ethoxyphenyl)-4-formyl pyrazole wth different aromatic amines.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The











Type (VII)       R = Aryl
1 9































Type - (VII) R = Aryl
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SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-1,N-PHENYL-
3-(p-ETHOXYPHENYL)-PYRAZOL-4-YL-AZOMETHINES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(p-ethoxyphenyl)-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C)  Preparation of N-(p-Chlorophenyl)-1,N-phenyl-3-(p-ethoxyphenyl)-pyrazol-
4-yl-azomethines
A mixture of 1,N-phenyl-3-(p-ethoxyphenyl)-4-formyl pyrazole(2.92gm, 0.01M)
and p-chloroaniline (1.27gm, 0.01M) was refluxed in ethanol (95%) for 10 hrs.with the
use of  gl CH3COOH(1ml) as catalyst. The contents were cooled and product isolated
was crystallised from ethanol. Yield 78%, m.p.160oC, (C24H20ClN3O; Found : C,
71.13; H, 5.02; N, 10.46 %; Required : C, 71.09%; H, 4.97 %; N, 10.40%).
TLC solvent system : Ethyl acetate:Hexane (2.7:7.3).
Similarly other substituted azomethines have been prepared. The physical data
are recorded in Table No. 7
(D) Antimicrobial activity of N-Aryl-1,N-phenyl-3-(p-ethoxyphenyl)-pyrazol-
4-yl-azomethines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 7.
11
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IR  SPECTRAL STUDY OF  N-(p -CHLOROPHENYL)-1,N-PHENYL-3-(p -
ETHOXYPHENYL)-PYRAZOL-4-YL-AZOMETHINE
Alkane C-H str. (asym.) 2923 2975-2950 413
-CH3 C-H str. (sym.) 2817 2880-2860
C-H i.p.def. (asym.) 1434 1470-1400
C-H o.o.p. def. (sym.) 1363 1390-1370
Aromatic C-H  str. 3049 3080-3030 414
C=C str. 1533 1585-1480
C-H i.p. def. 1101 1125-1090
C-H o.o.p. def 821 835-810
Pyrazole C=N str. 1583 1630-1590 415
moiety C-N str. 1078 1230-1020
C-Cl str. 756 830-560
Ether C-O-C str. (asym.) 1232 1275-1200 413
C-O-C str. (sym.) 1066 1075-1020
Schiff Base C=N str. 1645 1660-1580 415
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)



















1. 1.43-1.63 3H triplet -OCH2CH3 JCH3=6.3
2. 4.06-4.11 2H quartret -OCH2CH3  JCH2=7.0
3. 6.82-6.84 2H doublet Ar-Hgg’ Jgf=7.6
4. 6.99-7.01 2H doublet Ar-Hhh’  Jhi=8.7
5. 7.34-7.36 2H triplet Ar-Hbd -
6. 7.47-7.51 3H triplet Ar-Ha,c,e -
7. 7.60-7.62 2H doublet Ar-Hii’  Jih=8.7
8. 7.73 1H singlet CHy -
9. 7.76-7.78 2H doublet Ar-Hff’ Jfg=7.6




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
TABLE-7 : PHYSICAL CONSTANTS OF  N-ARYL1,N-PHENYL-3- (p-ETHOXYPHENYL)-PYRAZOL-4-YL-
AZOMETHINES
*TLC Solvent System :Ethylacetate : Hexane (2.7 :7.3)
7a C6H5- C24H21N3O 367 20 0.47 71 10.46 10.41
7b 4-OCH3-C6H4- C25H23N3O2 397 168 0.45 68 10.57 10.52
   7c 4-CH3-C6H4- C25H23N3O 381 159 0.52 60 11.02 10.96
7d 4-F-C6H4- C24H20FN3O 385 158 0.55 70 10.90 10.85
7e 4-Cl-C6H4- C24H20ClN3O 401 160 0.59 78 10.46 10.40
7f 4-Br-C6H4- C24H20BrN3O 446 154 0.53 73 9.41 9.35
7g 2-NO2-C6H4- C24H20N4O3 412 190 0.61 75 10.96 10.90
7h 3-NO2-C6H4- C24H20N4O3 412 205 0.50 58 10.26 10.21
7i 2-CH3-C6H4- C25H23N3O 381 184 0.60 68 11.02 10.97
7j 2,4-(Cl)2-C6H3- C24H19Cl2N3O 436 215 0.68 78 9.63 9.58
7k 3,4-(Cl)2-C6H3- C24H19Cl2N3O 436 228 0.54 62 9.63 9.59



























B. coccus 18 20 16 23 16 22 23 10 17 21 16 15 25 18 20 22 0
S. aureus 15 12 21 14 20 17 17 19 14 15 20 12 25 19 15 21 0
E. aerogenes 21 13 22 16 22 16 15 14 11 18 13 15 20 21 22 19 0
P. aeruginosa 18 16 17 18 14 14 18 21 17 14 14 22 22 21 16 23 0
A. niger 16 15 13 13 16 18 11 15 19 22 16 18 0 0 0 0 26





















It has been concluded from the experimental data that the compounds bearing
R=4-bromophenyl,2-nitrophenyl,2,4-dichlorophenyl and 4-fluorophenyl  have displayed
good activity against B.coccus. The compounds bearing R=4-tolyl have shown
considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E. aerogenes except the compound bearing R=phenyl,4-tolyl and 4-chlorophenyl.  While
the compounds bearing R= 3-nitrophenyl and  2-anisyl showed significant activity against
P. aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=2,4-dichlorophenyl  displayed highest activity against
A.niger.
The antibacterial activity was compared with standard drugs viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and greseofulvin.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYLAMINOMETHYL-
1,N-PHENYL-3-(p-ETHOXYPHENYL)-PYRAZOLES
The efficiency of arylaminomethyl derivatives as chemotherapeutic agents is well
established. To further assess the pharmacological profile of such a class of compounds,
we have synthesised arylaminomethyl derivatives of type (VIII) by selective reduction
of (Imine group) shiff’s base of (VII) with sodiumborohydride in controlled experimental
condition as shown in the reaction scheme.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The












   Type (VIII)       R = Aryl
119





































Type - (VIII) R = Aryl
REACTION SCHEME
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYLAMINOMETHYL-
1,N-PHENYL-3-(p-ETHOXYPHENYL)-PYRAZOLES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(p-ethoxyphenyl)-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of N-Aryl-1,N-phenyl-3-(p-ethoxyphenyl)-pyrazol-4-yl-
azomethines
See Part-VII, Section-I (C).
(D) Preparat ion of  4- (p -Fluorophenyl)aminomethyl -1 ,N-phenyl -3- (p-
ethoxyphenyl)pyrazole
Sodium borohydride (0.15M, 0.57g) was added to a methanolic solution
of N-(p-Flurophenyl)-1,N-phenyl-3-(p-ethoxyphenyl)-pyrazol-4-yl-azomethine (0.01M,
3.85gm) over a period of 30 minutes at temperature of  5-10oC. The reaction mixture
then kept over night at room tempeture. The excess of  borohydride was neutralized by
adding water and the product was extracted with ether.The ether extract was washed
with water untill extract is neutralised, then dried over anhydrous Na2SO4 and finally
the ether was evaporated to give aminomethyl derivative. Yield, 53%, m.p.
124oC.(C24H22FN3O; Found : C, 74.11; H, 5.72; N, 13.85 %; Required : C, 74.07%;
H, 5.67%; N, 13.80%).
TLC solvent system : Ethylacetate:Hexane (1.5 : 8.5).
Similarly other substituted arylaminomethy pyrazoles have been prepared. The
physical data are recorded in Table No.8.
(E) Antimicrobial activity of 4 - Aryla m i n o m e t h y l - 1 , N - p h e n y l - 3 - ( p-
ethoxyphenyl)pyrazole
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 8.
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Alkane C-H str. (asym.) 2923 2975-2950
-CH3 C-H str. (sym.) 2854 2880-2860
C-H i.p.def. (asym.) 1446 1470-1400
C-H o.o.p. def. (sym.) 1342 1390-1370
Aromatic C-H  str. 3045 3080-3030
C=C str. 1544 1585-1480
C-H i.p. def. 1114 1125-1090
C-H o.o.p. def  840 835-810
Pyrazole C=N str. 1598 1630-1590
moiety C-N str. 1053 1230-1020
C-Cl str. 756 830-560
Ether C-O-C str. (asym.) 1245 1275-1200
C-O-C str. (sym.) 1053 1075-1020
(overlapped)
C-N str. 1288
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PMR SPECTRAL STUDY OF 4-(p-FLUOROPHENYL)AMINOMETHYL-1,N-
PHENYL-3-(p-ETHOXYPHENYL)-PYRAZOLE
1. 1.40-1.43 3H triplet -OCH2CH3 JCH3=6.9
2. 4.02-4.07 2H quartret -OCH2CH3 JCH2=7.0
3. 4.55 2H singlet CHY,Z -
4. 6.74-6.76 2H doublet Ar-Hgg’ Jgh=8.2
5. 6.91-6.93 2H doublet Ar-Hhh’ Jhi=8.4
6. 7.21-7.23 2H doublet Ar-Hae Jab=8.5
7. 7.32-7.35 1H triplet Ar-Hc -
8. 7.46 1H singlet NH -
9. 7.47-7.51 2H triplet Ar-Hbd -
10. 7.62-7.64 2H doublet Ar-Hff’  Jfg=8.2
11. 7.76-7.78 2H doublet Ar-Hii’  Jih=8.4




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
TABLE-8 : PHYSICAL CONSTANTS OF  4-ARYLAMINOMETHYL-1,N-PHENYL-3-(p-ETHOXYPHENYL)-PYRAZOLES
*TLC Solvent System :Ethylacetate : Hexane (1.5 : 8.5)
8a C6H5- C24H23N3O 369 110 0.52 56 11.37 11.32
8b 4-OCH3-C6H4- C25H25N3O2 399 145 0.63 57 10.52 10.47
   8c 4-CH3-C6H4- C25H25N3O 383 120 0.58 61 10.96 10.93
8d 4-F-C6H4- C24H22FN3O 387 124 0.51 53 13.85 13.80
8e 4-Cl-C6H4- C24H22ClN3O 403 135 0.49 63 10.40 10.35
8f 4-Br-C6H4- C24H22BrN3O 448 140 0.56 55 9.37 9.33
8g 2-NO2-C6H4- C24H22N4O3 414 115 0.70 59 13.52 13.47
8h 3-NO2-C6H4- C24H22N4O3 414 132 0.69 62 13.52 13.47
8i 2-CH3-C6H4- C25H25N3O 383 146 0.52 53 10.96 10.91
8j 2,4-(Cl)2-C6H3- C24H21Cl2N3O 438 140 0.64 49 9.59 9.53
8k 3,4-(Cl)2-C6H3- C24H21Cl2N3O 438 158 0.68 55 9.59 9.55



























B. coccus 18 18 18 22 11 15 15 13 21 15 17 12 18 20 22 0
S. aureus 12 15 19 15 10 18 14 16 23 16 21 15 19 15 21 0
E. aerogenes 15 19 13 17 18 13 13 11 17 21 12 20 21 22 19 0
P. aeruginosa 18 21 15 21 22 11 18 18 13 13 14 13 21 16 23 0
A. niger 16 13 21 13 17 22 21 15 15 22 10 14 0 0 0 26





















It has been concluded from the experimental data that the compounds bearing
R=4-fluorophenyl and 2-tolyl  have displayed good activity against B.coccus. The
compounds bearing R= 2-tolyl,3,4-dichlorophenyl  have shown  considerable activity
against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E. aerogenes except the compound bearing R=2,4-dichlorophenyl.While the compounds
bearing R=4-chlorophenyl,4-fluorophenyl and 4-anisyl showed significant activity against
P. aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=4-bromophenyl,4-tolyl,2,4-dichlorophenyl and 2-
nitrophenyl  displayed highest activity against A.niger.
The antibacterial activity was compared with standard drugs viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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The five membered heterocyclic ring system 5-oxo-imidazolines have two
nitrogen atom at 1- and 3-positions and a carbonyl group at 5-position.
A. W. Hoffman191 for the first time discovered 5-oxo-imidazoline by heating
N’-diacetylethylene diamine in a steam of dry hydrogen chloride. A.Ladenburg192
prepared the same compound by fusing two equivalents of sodium acetate with one
equivalent of ethylene diamine dihydrochloride.
The drug molecules containing imidazolinone ring system are as under.
SYNTHETIC ASPECTS
Various methods have been reported for the synthesis of imidazolinones in
literature.193 Aminolysis of oxazolone with amine leads to the formation of imidazolinones
which has been reported in literature.194
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2. A. Saxena et al.196 have synthesized new imidazolinones (II).
3. Feng-Jun-Ca i  e t  a l .197 have  r epor t ed  5 - imidazo l inone  de r iva t ives
by microwaves irradiation.
4. Hisato Takeuchi et al.198 have synthesised imidazolinones by the reaction of
azido substituted imides with triphenylphosphine or tributylphosphine.
5. Laszlo Varga et al.199 have synthesized imidazolinones (IV) by the reac-
tion of  chalcone and guanidine.
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of a-acylamino acryclic acids obtained from the
condensation of azalactone and primary amines can be converted into imidazolinones as
shown in equation. The ring closure can be affected under a variety of conditions.

















































Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline
and phenotolamine as adrenergic blocking agents. Various imidazolinones are known to

































R’-NH2, DryC5H5N/Abs. C2H5OH, K2CO3
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V. Akyoshi et. al.222 have prepared some new imidazolinone derivatives (V)
and reported their herbicidal activity. Agrochemical activity of imidazolinones have been
reported by Kolhe and co-workers223.
Antifungal activity of imidazolinones towards Aspergillus fumigutus is investigated
by T. Kitazaki et . al224. Ozaki Satoshi et. al.225 have reported imidazolinones useful
as analgesic, antagonists against tolerance to narcotic analgesics typified by morphine,
agents for the treatment of obesity and drugs for ameliorating brain function. Lacroix
Guy et. al.226 have synthesised 5-imidazolinones as possible agrochemical fungicide.
Rama Sharma and co-workers227 have formulated 5-oxo-imidazolines possessing
potential antimicrobial activity.
K. K. Awasthi et. al.228 (VI) have synthesised some new imidazolinone
derivatives and reported their antimicrobial activity.
 Imam Hidayat et. al.229  have reported ALS-inhibitory activity of imidazolinones.
Keun-Jin Oh et. al.230 have investigated some imidazolinone derivatives which possess
the enzymatic activity as well as the binding affinity for the cofactor FAD (Flavin adenine
dinucleotide). Stefama Lauter and Co-worker231 have isolated imidazoline by using
different methods and tested for the treatment of cytokine release. Imidazoline derivatives
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Ding, Ming-Wu et. al.233 have prepared novel imidazolines and reported their
antifungal activity. Irene M. L. et. al.234 have investigated some imidazolinone derivatives
possessing antireteroviral activity. Zhong Jin235 has found imidazoline derivatives (VII)
as cytotoxic towards several tumor cell lines.
Jean M. R. et. al.236 have discovered imidazolinones and tested as antileishmanial
agents.
CONTRIBUTION FROM OUR LABORATORY
Dr. H. H. Parekh and co-workers237 have synthesised 5-oxo-imidazolines as
novel bioactive compounds derived from benzimidazole. Parikh et. al.238 have reported
4-(4’-arylidene-2’-phenyl-5’-oxo-imidazolin-1’-yl)-benzophenone and screened for their
antimicrobial activity.  A. R. Parikh et.al.239 have reported  5-oxo-imidazolines as bio-
logically active agents. Hasmukh Kanjaria and co-workers240 have described
imidazolinones as potential antimicrobial agents.
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Satyen P. Patel and co-workers242 have synthesised imidazolines as biologically
active agents. Joshi H. et. al.243 have synthesised imidazolinones as potent
anticonvulsant agents.
Recently, Aleksey N. Vasiliev et. al.244 have synthesised imidazolinone derivatives
(IX) and reported their herbicidal activity.
C. Alister and co-workers245 have documented herbicidal activity of
imidazolinone derivatives. E. Jayachandran et. al.246 have reported imidazolinones as
antimicrobial agents. Imidazolinone derivatives as acetohydroxyacid  synthase (AHAS)
inhibitors have been suggested by Tan S. and co-workers247.
The development of efficient and selective synthesis of imidazolinones has attracted
increasing attention because they often bring about unique pharmacodynamic activities.
In search of biologically potent imidazolinone derivatives, it was considered worthwhile
to synthesise imidazolinones which have been described as under.




















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-PHENYL-4-
(1’ ,N-PHENYL-3’-p -ETHOXYPHENYL-4’-PYRAZOLYLMETHINE)-
IMIDAZOLIN-5-ONES
Imidazolinone derivatives possess varieties of biological and pharmacological
properties. Here, we report the synthesis of some new 5-oxo-imidazolines of type (IX).
The strategy employed for the synthesis of desired compounds involved the condensation
of azlactones with different aromatic amines shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The















Type (IX)     R = Aryl
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-PHENYL-4-
(1’ ,N-PHENYL-3’-p -ETHOXYPHENYL-4’-PYRAZOLYLMETHINE)-
IMIDAZOLIN-5-ONES
(A) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(B) S y n t h e s i s  o f  2 - P h e n y l - 4 - ( 1 ' , N - p h e n y l - 3 ' - p - e t h o x y p h e n y l - 4 ’-
pyrazolylmethino)-oxazolin-5-one
A mixture of 1,N-phenyl-3-p-ethoxyphenyl-4-formyl pyrazole (2.92 g,
0.01M), acetic anhydride (7.6ml, 0.075M), sodium acetate (2.0 g, 0.025M) and
hippuric acid (4.4g, 0.025M) was heated on waterbath for 4 hrs. Resulting mass was
poured onto crushed ice, filtered, washed with hot water and crystallised from
ethanol. Yield 65%, m.p.143oC, (C27H11N3O3 : Required C : 74.47; H : 4.86;     N: 9.65;
Found C : 74.40; H : 4.80; N : 9.61%).
TLC solvent system : Ethyl acetate : Hexane (1.5 : 8.5)
(C) Synthes is  of  1 ,N-p -Chlorophenyl-2-phenyl-4- (1 ' ,N-phenyl-3 ' -p -
ethoxyphenyl-4'-pyrazolylmethino)-imidazolin-5-one
A mixture of 2-phenyl-4-(1',N-phenyl-3'-p-ethoxyphenyl-4'-pyrazolylmethino)-
oxazolin-5-one (4.35 g, 0.01M) and p-chloroaniline(1.06g, 0.01M) in dry pyridine (20
ml) was refluxed for 12 hrs. Resulting mass was poured on to crushed ice and neutralised
with HCl, filtered and crystallised from DMF. Yield,  60%, m.p.170oC (C33H25ClN4O2
: Required C: 72.72; H: 4.62; N: 10.28; Found : C: 72.68; H: 4.57; N: 10.23%).TCL
solvent system : Acetone : Benzene (1.5 :8.5).
Similarly other imidazolin-5-ones have been prepared. The physical data
are recorded in Table No. 9.
(D) Antimicrobial activity of 1,N-Aryl-2-phenyl-4-(1’,N-phenyl-3’-p-ethoxy
phenyl-4’-pyrazolylmethine)- imidazolin-5-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 9
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-p-CHLOROPHENYL-2-PHENYL-4-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-4'-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONE
Alkane C-H str. (asym.) 2956 2975-2950 413
-CH3 C-H str. (sym.) 2873 2880-2860
C-H i.p.def. (asym.) 1458 1470-1435
C-H o.o.p. def. (sym.) 137 1390-1370
Aromatic C-H str. 3026 3080-3030
C=C str. 1510 1585-1480 414
C-H i.p. def. 1105 1125-1090
C-H o.o.p. def 827 835-810
Pyrazole C=N str. 1568 1630-1560 415
moiety C-N str. 1166 1230-1020
Ether C-O-C str. (asym.) 1257 1275-1200 413
C-O-C str. (sym.) 1058 1075-1020
Imidazolinone C=O str. 1714 1770-1655 414
ring C=N str. 1637 1650-1550
C-N str. 1257 1260-1220
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)

























1. 1.44-1.47 3H triplet -OCH2CH3 JCH3=6.7
2. 3.98-4.10 3H quartet -OCH2CH3 JCH2=7.0
3. 6.82-6.85 2H doublet  Ar-Hgg’ Jgf=8.6
4. 7.04-7.06 2H doublet  Ar-Hii’ Jih=8.8
5. 7.36-7.41 2H doublet  Ar-Hjn’  Jjk=8.7
6. 7.41-7.47 3H multiplet  Ar-Hb,c,d -
7. 7.55-7.62 3H multiplet  Ar-Hk,l,m -
8. 7.62-7.64 2H doublet  Ar-Hhh’ Jhi=8.8
9. 7.87-7.89 2H doublet  Ar-Hff’ Jfg=8.6
10. 7.99-7.89 1H singlet  CHy
11. 8.15-8.17 2H doublet  Ar-Hae Jab=8.7




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R C=O str.










































































































































    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %               Calcd.       Found
1     2        3          4          5          6                  7                   8        9
TABLE-9 : PHYSICAL CONSTANTS OF 1,N-ARYL-2-PHENYL-4-(1’ ,N-PHENYL-3’-p-ETHOXYPHENYL 4’-
PYRAZOLYL-METHINE)-IMIDAZOLIN-5-ONES
*TLC Solvent System : Acetone : Benzene (1.5 : 8.5)
9a C6H5- C33H26N4O2 510 198 0.57 68 10.97 10.92
9b 4-Cl-C6H4- C33H25ClN4O2 544.5 170 0.49 60 10.28 10.23
   9c 3,4-(Cl)2-C6H3- C33H24Cl2N4O2 579 148 0.48 79 9.67 9.61
9d 4-Br-C6H4- C33H25BrN4O2 589 159 0.67 60 9.50 9.45
9e 4-F-C6H4- C33H25FN4O2 528 118 0.53 53 10.60 10.54
9f 3-Cl,4-F-C6H3- C33H24ClFN4O2 562.5 221 0.55 58 9.95 9.92
9g 2-OCH3-C6H4- C34H28N4O3 540 168 0.49 62 10.36 10.31
9h 4-OCH3-C6H4- C34H28N4O3 540 201 0.52 66 10.36 10.33
9i 2-CH3-C6H4- C34H28N4O2 524 206 0.60 63 10.68 10.62
9j 4-CH3-C6H4- C34H28N4O2 524 156 0.59 72 10.68 10.64
9k 2-NO2-C6H4- C33H25N5O4 555 177 0.63 69 12.61 12.57
























B. coccus 16 21 16 18 17 20 16 21 18 14 17 21 25 18 20 22 0
S. aureus 20 16 18 24 15 17 23 17 18 22 19 14 25 19 15 21 0
E. aerogenes 14 15 19 14 22 18 14 14 14 20 16 20 20 21 22 19 0
P. aeruginosa 15 17 13 23 20 16 19 18 21 17 16 15 22 21 16 23 0
A. niger 16 19 22 15 17 19 17 19 20 20 13 23 0 0 0 0 26

























From the experimental data it has been observed that all the compounds of type
(VII) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R=4-chloro
phenyl, 4-methoxyphenyl and 4-nitrophenyl against B.coccus. The compounds bearing
R=4-bromophenyl ,2-methoxyphenyl and 4-tolyl have highly inhibited the growth of
S.aureus.
Compounds with R=4-fluorophenyl showed significant activity against Aerogenes.
While the compounds bearing R=4-bromophenyl and 2-tolyl have fairly inhibited the
growth Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds were active against A.niger. Maximum activity was observed
by the compounds bearing R=3,4,-dichlorophenyl and 4-nitrophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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Biosignificant pyridones form a component in a number of useful drugs and
are associated with many biological, pharmaceutical and therapeutic activities. Pyridones,
with a carbonyl group at position-2 (I) have been subject of extensive study in the recent
years. Synthetic pyridone derivatives contribute much to the searchable literature of
pyridone derivatives in huge libraries owing to their wide applicability in different fields.
Some 2-pyridones, which are pharmacologically important are as under: eg.
amrinone(II), ciclopirox(III) and methylprylon (IV).
SYNTHETIC ASPECTS
Different methods for the preparation of cyanopyridones are as follows :
1. W. Russel Bowman et. al.248 have synthesised cyanopyridones from 2,6-
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2. Rajul Jain et. al.249 have synthesised 3-cyano-2-pyridone by the reaction of
various enones with cyanoacetamide in presence of t-BuOK in DMSO under
O2 atmosphere.
3. K. Follkers and S. A. Harris250 have synthesised 3-cyano-2-pyridone by the
condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
MECHANISM
 The addition reaction between ethylcyano acetale and a, b-unsaturated ketone  yield
cyanopyridone via Michael addition. Here, a, b-unsaturated compound is known as acceptor
and active methylene group containing compound is known as addender. It involves

































R1, R2, R3= Alkyl
(VI)
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Pyridone derivatives have been found to possess variety of therapeutic





(e) Angitensin II antagonist256-258
(f) Antiviral259
(g) AntiHIV260
Peter and co-workers261 have described pyridinylmethyl substituted pyridines
and pyridones as angitensin II antagonist. H. Posnes262 have synthesized 2-pyridones
and 2-pyrones as physiologically active compounds. Mukhtar Hussain Khan and co-
workers263,264 have prepared 2-pyridone derivatives (VIII) and (IX) which possess
insecticidal and pesticidal activity.
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Morishita Koji et al.265 have synthesized m-(2-oxo-l,2-dihydropyridyl) urea  de-
rivatives (X) possessing cholesterol acyltransterase (ACAT) inhibitory activity and
are useful for the treatment of hyperlipidemia and arteriosclerosis.
Collins et al.266 have prepared heteroaryl pyridones as GABA a,b ligands (XI).
Pedneker267 have synthesized fused 2-pyridone derivatives (XII), (XIII) and (XIV) as
useful heterocyclic moieties as they possess broad spectrum of biological activities such
as antiviral, CNS depressant, bactericidal and ulcer inhibitor.
E. Amer268 prepared 3-cyano-2-pyridone derivatives displaying significant
antimicrobial activity. Abou El-Fotooh and co-workers269. have demonstrated pyridones
as anticancer agent. M. G. Nizamuddin et al.270 have prepared cyanopyridone derivatives
(XV) and documented their antifungal activity. Tanaka Akira et al.271 have prepared






































(XI) (XII) (XIII) (XIV)
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Xi Qi et. al.272 have investigated cyanopyridones useful as phosphatase inhibitors
and studied their biological activities. Darcq Michael. G. et. al.273 have discovered
some new cyanopyridone derivatives which showed in vitro HCV NS5B inhibitory activity
and exhibited IC50 in the range of 0.0001 µM to 100 µM. Their pharmaceutical
compositions are useful for treating HCV infections. Isobe Y. et. al.274 have prepared
pyrimidine diones and evaluated them as antiallergic agents. Nersesyan K. et. al.275
have investigated some new cyanopyridones possessing genotoxic activity in murine cells
and antitumor activity.
Recently, Devdas B. et. al.276 have synthesised pyridone derivatives which are
useful for treating diseases and conditions caused or exacerbated by  unregulated P38
MAP kinase and/or TNF activity, such as inflammation, ischemia, viral infections and
autoimmune diseases. Wang S. and co-workers277 have prepared 2-pyridones containing
tricyclic alkaloid derivatives as potential inhibitors of tumor cell proliferation by
regioselective intramolecular N- and C-acylation of 2-pyridone. A novel series of pyridone
inhibitors has been identified through pharmacophore analysis as potent and selective
VLA-4 integrin antagonists by Jason Witherington et. al.278 Jiang Q. and co-workers279
have identified a series of novel pyridones as kinase inhibitors of ALK.
Thus the important role played by cyanopyridone nucleus for various physiological
activities prompted us to explore cyanopyridone chemistry by synthesing its derivatives
bearing pyrazole ring system of therapeutic importance, in order to achieving compounds
having better drug potential which has been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
























SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-(1',N-
PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-6-ARYL-1,2-DIHYDRO-2-
PYRIDONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives by the
condensation of chalcones of type-(I) with ethylcyanoacetate in the presence of
ammonium acetate as shown under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography. .
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The

















Type - (X)    R = Aryl
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Type - (X) R = Aryl
REACTION SCHEME
15




SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-(1',N-
PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-6-ARYL-1,2-DIHYDRO-2-
PYRIDONES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 3-Cyano-4-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-
6-(p-bromophenyl)-1,2-dihydro-2-pyridone
 A mixture of 1-(p-bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-
yl)-2-propen-1-one (4.87 g, 0.01 M), ethylcyanoacetate (1.13 g, 0.01 M) and ammonium
acetate (6.16 g, 0.08 M) in absolute alcohol was refluxed for 12 hrs. The reaction
mixture was poured on to crushed ice and product was isolated and crystallised from
ethanol. Yield 68%, m.p. 198oC (C29H21BrN4O2; Required : C, 64.81; H, 3.94; N,
10.43;  Found : C, 64.75; H, 3.90; N, 10.39%).
TLC solvent system : Acetone : Benzene (3 : 7).
Similarly other substituted pyridones have been prepared. The physical data are
recorded in Table No. 10.
(E) Antimicrobial activity of 3-Cyano-4-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-6-aryl-1,2-dihydro-2-pyridones
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.10.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-p-ETHOXYPHENYL-
PYRAZOL-4'-YL)-6-(p-BROMOPHENYL)-1,2-DIHYDRO-2-PYRIDONE
Alkane C-H str. (asym.) 2922 2975-2950 413
-CH3 C-H str. (sym.) 2852 2880-2860
C-H i.p.def. (asym.) 1454 1470-1435
Aromatic C=C str. 1537 1585-1480 414
C-H i.p. def. 1099 1125-1090
C-H o.o.p. def. 837 835-810
Pyrazole C=N str. 1596 1630-1590 415
moiety C-N str. 1155 1230-1020
Ether C-O-C str. (asym.) 1236 1275-1200 413
C-O-C str. (sym.) 1072 1075-1020
Pyridone ring CºN str. 2218 2240-2120 413
C=O str. 1643 1760-1655
N-H str. 3423 3450-3250
N-H def. 1596 1650-1580
(overlapped)
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)























1. 1.26-1.49 3H triplet -OCH2CH3 JCH3=6.0
2. 4.07-4.14 2H quartret -OCH2CH3 JCH2=6.0
4. 7.002-7.030 2H doublet Ar-Hgg’ Jgf=8.4
3. 7.28 1H singlet CHy -
5. 7.33-7.37 1H triplet Ar-Hc -
6. 7.47-7.52 2H triplet Ar-Hbd -
7. 7.61-7.63 4H doublet Ar-Hff’,Ar-Hhh’ Jfg=8.4
8. 7.78-7.87 4H multiplet Ar-Ha,e, Ar-Hii’ -




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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I R  S P E C T R A L  S T U D Y  O F  3 - C YA N O - 4 - ( 1 ' , N - P H E N Y L - 3 ' -
( p-ETHOXYPHENYL-PYRAZOL-4'-YL)-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R    C=O str.
      4a C6H5- 1650 2217
4b 4-NH2-C6H4- 1649 2225
4c 4-Cl-C6H4- 1643 2219
4d 4-Br-C6H4- 1643 2218
4e 4-F-C6H4- 1654 2218
4f 2-OH-C6H4- 1643 2214
4g 4-OH-C6H4- 1649 2219
4h 4-OCH3-C6H4- 1646 2212
4i 4-CH3-C6H4- 1642 2220
4j 3-NO2-C6H4- 1659 2214
4k 4-NO2-C6H4- 1637 2218























































































































































































    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
10a C6H5- C28H26N4O2    458  190 0.59 68    12.22      12.17
10b 4-NH2-C6H4- C29H22N4O2    473  215 0.53 59    14.79      14.73
10c 4-Cl-C6H4- C29H21ClN4O2    492.5  260 0.49 63    11.37      11.33
10d 4-Br-C6H4- C29H21BrN4O2    537  198 0.62 68    10.43      10.39
10e 4-F-C6H4- C29H21FN4O2    476  235 0.63 63    11.76      11.71
10f 2-OH-C6H4- C29H22N4O3    474  230 0.53 72    11.81      11.75
10g 4-OH-C6H4- C29H22N4O3    474  177 0.59 80    11.81      11.77
10h 4-OCH3-C6H4- C30H24N4O3    488  157 0.53 59    11.47      11.42
10i 4-CH3-C6H4- C30H24N4O2    472  225 0.48 70    11.86      11.83
10j 3-NO2-C6H4- C29H21N5O4    503  203 0.56 56    13.91      13.87
10k 4-NO2-C6H4- C29H21N5O4    503  156 0.63 69    13.91      13.85
10l 2-C4H3S- C27H20N4O2S    464  157 0.48 72    12.06      12.01
TABLE-10: PHYSICAL CONSTANTS OF 3-CYANO-4-(1',N-PHENYL-3'-P-ETHOXYPHENYL-PYRAZOL-4'-YL)-
6- ARYL-1,2-DIHYDRO-2-PYRIDONES.
























B. coccus 14 23 17 17 19 14 16 16 14 20 16 18 25 18 20 22 0
S. aureus 16 19 21 18 15 20 14 18 19 14 13 21 25 19 15 21 0
E. aerogenes 15 16 22 18 19 14 19 21 13 23 18 17 20 21 22 19 0
P. aeruginosa 21 17 21 22 19 13 17 16 16 14 15 19 22 21 16 23 0
A. niger 19 18 16 18 22 16 15 16 21 18 23 17 0 0 0 0 26

























From the experimental data it has been concluded that all the compounds were
mildly active against Gram positive bacterial strains except R=4-chlorophenyl,4-
aminophenyl  which showed highest activity against B.coccus and R=2-thienyl which
showed highest activity against S.aureus.
In case of Gram negative bacterial strains, the compounds bearing R=4-
chlorophenyl, 4-methoxyphenyl and 3-nitrophenyl have exhibited significant activity
against Aerogenes. The compounds bearing R=phenyl, 4-chlorophenyl and 4-
bromophenyl have shown maximum activity against Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity was
shown by the compounds bearing R=4-fluorophenyl, 4-tolyl and 4-nitrophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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Pyridine is the parent of the series of compounds that is important in
pharmaceutical, agriculture and industrial chemistry. Among a wide range of
3-cyanopyridines acquired a special attention due to their wide range of therapeutic
activities. Most derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However the
simple pyridine compounds are prepared by the cyclization of aliphatic raw materials.
The pyridine nucleous is found in a large number of commonly used drugs which
have diverse pharmacological activities. Interest in the synthesis of multicyclic pyridine
containing compounds have increased in recent years because of their biological and
pharmacological activities.
SYNTHETIC ASPECTS
Different method for the preparation of 3-cyanopyridines are available in
literature.280-284 The well known methods are:
1. Sakurai and Midorikaw285,have reported that malononitrile reacts with a,b-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines(I).
2. Samour and co-workers prepared substituted  cyanopyridines by the condensation of
chalcones with ethyl acetoacetate and malononitrile in the presence of ammonium
acetate.286
3. Amalia Ubeda and co-workers prepared 2-amino-3-cyanopyridine derivatives
using arylidene malononitrile + lithium isopropyl amide and DMF dichloride.287
4. Dao-Lin& Kimiaki288 have prepared 2-methoxy-3-cyanopyridine derivatives














Cyanopyridines have attracted considerable attention as they appeared of interest
to possess antibacterial, anticholestermic, antifungal, antihypertensive and antidiabetic









Hussan M. and co-workers297 have prepared 3-cyanopyridines and reported
their pharmacological activity.U. Teu and co-workers298 have shown cyanopyridines
as agrochemical fungicides. H. Yoshida et al.299 have studied the antihistamic and
antiallergic activity of 3-cyanopyridine derivatives.
Gadaginamath and co-workers300 have synthesized various cyanopyridyl
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M. Bernard et al.301 have reported anticonvulsant activity of 3-cyanopyridines.
D. G. Bhatt et al.302 have prepared 3-cyanopyridines as an immunosuppressive agent.S.
Guru et al.303 have synthesized various cyanopyridyl derivatives (IV) and documented
their multiple biological activities.
John A. Tucker et al.304 have synthesized novel piperazinyl oxazolidinone
containing cyanopyridine (V) as an antibacterial agent.
Manna Fedele and co-workers305 have reported the antiinflammatory activity
of 3-cyanopyridines.Hammana Abou and co-workers306  have studied anticancer and
anti-HIV activity of 3-cyanopyridines. Abdallah Navine et al.307 have prepared
cyanopyridine derivatives which showed analgesic and antiinflammatory activity.
Abd El-Galil and co-workers308 have prepared 3-cyanopyridines (VI) and studied their
pharmacological activity.El-Nabawia et al.309 have prepared 2-amino-3-cyano pyridine
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S. V. Roman et al.310 have synthesized 2-amino-3-cyanopyridines and reported
their biological activity. El-Taweel and co-workers311 have prepared cyanopyridine
derivatives and showed their significant biological activity.Pyachenko U. D. et al.312
have synthesized some cyanopyridines which are useful in the treatment of retroviral
disease.Abu and co-workers313 have prepared novel fused cyanopyridines (VIII) for
the treatment and preparation of systemic fungal infection.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a valuable
therapy for diabetes.Marco J. L. et al.314 have synthesized acetylcholinesterase
inhibitors.Edwin B. Villhauer and co-workers315 have reported the first use of
solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a
solution-phase synthesis that is practical up to the multikilogram scale. One compound,
NVP-DPP728 (X), is profiled as a potent, selective and shortacting DPP-IV inhibitor
that has excellent oral bioavailability and potent antihyperglycemic activity.
Rosentreter Ulrich et al.316 have synthesized a new cyanopyridine as receptor
agonists in the treatment of cardiac or urogenital disease cancer, inflammation,
neurodegenerative disease(XI).Moustafa M. A. et al.317 have prepared cyanopyridne





















O (CH2) n OR
(X)
165
Design and Synthesis ...
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212
 Recently Eduardo H. S. Sousa et al.318 documented thionicotinamide
coordinated to the a model system for the in vitro activation of thioamides antituberculosis
drugs.Gary T. Wang and co-workers 319 have synthesized of o-trifluoromethylbiphenyl
substituted 2-amino-nicotinonitriles as inhibitors of farnesyl transferase(XI)
Abdel-Galil E,Amr and Mohamed M. Abdulla320 have synthesized heterocyclic
pyridine derivatives (XII) fused with steroidal structure.
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity with least side effect have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
METHOXY-3-CYANO-4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL)-
PYRAZOL-4'-YL]-6-ARYL-PYRIDINES


























SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-METHOXY-3-CYANO-
4-[1',N-PHENYL-3'-(p-ETHOXYPHENYL) PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
The pyridine nucleus is found in a large number of commonly used drugs which
have diverse pharmacological activities. To achieving better drug potency cyanopyridine
derivatives of type (XI) have been prepared by the condensation of chalcones of type
(I) with malononitrile in the presence of sodium methoxide.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.



























































Type - (XI) R = Aryl
REACTION SCHEME
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-METHOXY-3-CYANO-
4 - [ 1 ’ , N - P H E N Y L - 3 ’ - p - E T H O X Y P H E N Y L - P Y R A Z O L - 4 ’ - Y L ) - 6 - ( p -
BROMOPHENYL)-PYRIDINES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 2-Methoxy-3-cyano-4-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-6-(p-bromophenyl)-pyridine
A mixture of  1-(p -bromophenyl)-3-(1 ' ,N-phenyl-3 '-p -ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one(4.87 g, 0.01 M), malononitrile (0.66 g, 0.01 M)
and ammonium acetate (2.31 g, 0.03 M) in sodium methoxide(30 ml) and sodium
methoxide (10 ml) (6.61g, 0.08M) dissolved in absoulte alcohol  was refluxed for 8
hrs., poured into crushed ice. The solid obtained was filtered, washed with water and
crystallised from DMF. Yield 62%, m.p.168oC. (C30H23BrN4O2; required: C, 65.34;
H, 4.20; N, 10.16%; found: C, 65.30; H, 4.14; N, 10.10%).
TLC Solvent System :Ethyl acetate : Hexane (2 : 8)
Similarly other 2-methoxy-3-cyano-4-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-6-(p-bromophenyl)-pyridine were synthesized. The physical data are
recorded in Table No.11.
[D] Antimicrobial activity of 2-Methoxy-3-cyano-4-(1',N-phenyl-3'-p-
ethoxyphenyl-pyrazol-4'-yl)-6-aryl-pyridine
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.11.
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IR SPECTRAL STUDY OF 2-METHOXY-3-CYANO-4-[1',N-PHENYL-3'-
(p-ETHOXYPHENYL) PYRAZOL-4'-YL]-6-(p-BROMOPHENYL) PYRIDINE

















Alkane C-H str. (asym.) 2943 2975-2950 413
-CH3 C-H str. (sym.) 2846 2880-2860
C-H i.p.def. (asym.) 1461 1470-1435
C-H o.o.p. def. (sym.) 1344 1390-1370
Aromatic C=H str. 3076 3080-3010 414
C=C str. 1500 1585-1480
C-H i.p. def. 1095 1125-1000
C-H o.o.p. def 825 835-810
Pyrazole C=N str. 1587 1630-1590 415
moiety C-N str. 1157 1230-1020
C-Br str. 758 600-800 413
Ether C-O-C str. (asym.) 1242 1275-1200 413
C-O-C str. (sym.) 1037 1075-1020
Pyridine ring CºN str. 2219 2240-2120 420
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PMR SPECTRAL STUDY OF 2-METHOXY-3-CYANO-4-[1',N-PHENYL-3'-
(p-ETHOXYPHENYL) PYRAZOL-4'-YL]-6-(p-FLUOROPHENYL) PYRIDINE






















1. 1.45-1.61 3H triplet -OCH2CH3 JCH3=6.9
2. 4.08-4.20 2H quartret -OCH2CH3 JCH2=7.0
3. 4.20 3H singlet -OCH3 -
4. 6.93-6.95 2H doublet Ar-Hgg’  Jgf=8.7
5. 7.08-7.11 2H triplet Ar-Hbd -
6. 7.35 1H singlet Ar-Hy
7. 7.35-7.39 1H triplet Ar-Hc -
8. 7.50-7.52 4H multiplet Ar-Hjj’Ar-Hff’ Jfg=8.7
9. 7.76-7.78 2H multiplet Ar-Ha,e
10. 7.82-7.84 2H doublet Ar-Hkk’ Jkj=8.2




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R


































































































































































    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
TABLE-11 : PHYSICAL CONSTANTS OF 2-METHOXY-3-CYANO-4-[1',N-PHENYL-3'-p-ETHOXYPHENYL)
PYRAZOL-4'-YL]-6-ARYL PYRIDINES
*TLC Solvent System :Ethyl acetate : Hexane (2 : 8)
11a C6H5- C30H24N4O2    472  154 0.50 65    11.86      11.80
11b 4-OCH3-C6H4- C31H26N4O3    502  196 0.54 59    11.15      10.10
11c 4-CH3-C6H4- C31H26N4O2               486  244 0.62 70    11.51      10.46
11d 4-Cl-C6H4- C30H23ClN4O2    506  186 0.69 63    11.05      10.45
11e 4-F-C6H4- C30H23FN4O2    490  201 0.53 60    11.42      11.38
11f 4-Br-C6H4- C30H23BrN4O2    551  168 0.54 62              10.16      10.10
11g 4-OH-C6H4- C30H24N4O3    488  199 0.57 69    11.47      11.42
11h 2-OH-C6H4- C30H24N4O3    488  180 0.66 70    11.47      11.41
11i 4-NO2-C6H4- C30H23N5O4    517  147 0.51 59    13.53      13.47
11j 3-NO2-C6H4- C30H23N5O4    517  150 0.56 60    13.53      13.48
11k 2-C4H3- C28H22N4O2S    476  178 0.55 63    11.71      11.66
























B. coccus 17 16 13 22 16 14 17 18 23 12 16 19 25 18 20 22 0
S. aureus 19 18 11 17 24 23 14 19 12 17 10 18 25 19 15 21 0
E. aerogenes 20 15 21 17 15 14 12 12 15 16 14 13 20 21 22 19 0
P. aeruginosa 14 11 15 23 22 16 19 14 16 21 12 17 22 21 16 23 0
A. niger 18 16 21 18 23 15 12 14 18 19 16 14 0 0 0 0 26

























From the experimental data it has been concluded that all the compounds were
mildly active against Gram positive bacterial strains except R=4-chlorophenyl and 4-
nitrophenyl which showed highest activity against B.coccus and R=4-bromophenyl and
4-fluorophenyly  which showed highest activity against S.aureus.
In case of Gram negative bacterial strains, the compound bearing R= 4-tolyl
have exhibited significant activity against E.aerogenes. The compounds bearing R=3-
nitrophenyl,4-chlorophenyl and 4-fluorophenyl   have shown maximum activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity was
shown by the compounds bearing R=4-tolyl and 4-fluorophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
177
Design and Synthesis ...
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212




Isoxazole is a five membered heterocyclic compound having two hetero atom:
oxygen at position 1 and nitrogen at position 2.  It was shown to possess typical properties
of an aromatic system  under certain reaction conditions. Particularly in reducing or
basic media, it becomes highly labile, yet it is easily cleaved when necessary.Thus,
isoxazoles are very useful intermediates  since the ring system stability allows the
manipulation of substituents to give functionally complex derivatives. Consequently,
isoxazole have become an important synthetic tool..
Claisen321 first reported an isoxazole (I) for a product from the reaction of 1,3
diketone with hydroxylamine. The next important contribution to the chemistry of isoxazoles
was made by Quelico322 in 1945, when he began to study the formation of isoxazoles
from nitrile N-oxide and unsaturated compounds.
SYNTHETIC ASPECTS
Isoxazoles can be prepared by various methods, which are described as under.
1. Tayade V. B. et al.323 synthesized some new 3,5-diarylisoxazoles from the
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in presence
of alkali.
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3. Crawley and Fan Shawe325 prepared isoxazole from a,b-unsaturated carbonyl
compounds, hydroxyl amine hydrochloride and KOH in methanol.
4. Issa and Loghman326 have synthesised isoxazoles (IV) from activated
acetylenes and alkyl 2-nitroethanoates in the presence of triphenylphosphine.
 MECHANISM
THERAPEUTIC IMPORTANCE
A class of isoxazole derivatives has been disclosed as having immuno
suppressant activity. These heterocycles are rapidly converted in vivo to ring opened
metabolites, hydroxyalkylidene-cynoacetamides, which we believed to be the active
therepeutic agents. Leflunomide(V)  is the lead compound of this new group of isoxazole








































































Design and Synthesis ...
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212
1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234567890123456789012345678901212
The psysiological effects of this classs of compounds, analogues of A77 1726(VI)
and the parent isoxazoles were disclosed as useful for treatment of cancer327.
These compounds exert an antiproliferactive effect through inhibition of receptor
tyrosine kinases and have little effect on proliferation of normal cells since their
inhibitory effect on DHOdehase is weak.TheDihydro isoxazoles can be used as linkers
for joining chemically sensitive moieties.This is the case for isoxazole-linked
nitroimidazole-carborane (VII) used for targeting hypoxic tumors328.
Some isoxazole analogs of retinoids exhibited good antiproliferative activity and
capability to induce differentiaon  in vitro culture tumor cell lines329.Compound (VIII)
is a representative example of bis-isoxazole derivatives disclosed to have anticancer
properties330.
The compound (IX) is chosen among a wide series of 1-amino-3-phenoxy
propane derivatives claimed as antineoplastic enhancers which are able to modulate the
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R. Ulrich et. al.349 have synthesised isoxazole derivatives and reported their
adrenergic antagonist activity. Qi Chuanmin et. al.350 have discovered isoxazoles as
herbicidal. Wu Chengde et. al.351 have synthesised isoxazole derivatives as endothelin
activity modulators. Some of the compounds exhibited IC50 values of 0.0015 ± 0.0014
mM for ETA receptors and 0.324 ± 0.78 mM for ETB receptors. Caroline and co-workers352
have studied isoxazoles which have been used for the clinical trials of asthama. Bente
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Barbachyn M. R. et al.354 have described the phenylisoxazolines as novel and
viable antibacterial agents active against Gram-positive pathogens. Salter M. W. et al.355
have prepared some novel isoxazole as cellular neuroplasticity mechanisms mediating
pain persistence.Mehlisch D. R. et al.356 have synthesized isoxazole derivative as
analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain. Welsing
P. M. et al.357 have documented the isoxazoles as tumor necrosis factor-blocking agents
and leflunomide for treating rheumatoid arthritis in the Netherlands.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh et al.358 have synthesised 3-(p-methoxyphenyl)-5-(2'-chloro-7'-
methylquinolin-3'-yl)-isoxazole (XI) and studied their biological activity.
V. B. Patel and co-workers359 have prepared isoxazoles bearing sulphonamide
moiety and reported their antimicrobial activity. Ketan Hirpara et. al.360 have synthesised
isoxazoles as antitubercular agents. A. V. Dobaria et. al.361 have described the isoxazole
derivatives and their use as antimicrobial agents. B. P. Kansagara et. al.362 have dem-
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Recently,  H. S. Yathirajan et. al.363 have synthesised novel 4-(5-methyl-3-
phenylisoxazole-4-yl) benzene-sulfonamide ethylmethyl ketone used as non-sterodal
antiinflammatory drug.Bente Frolund et. al.364 have reported tetrazolyl isoxazole amino
acids as ionotropic glutamate receptor antagonists. Bryan H. Norman et. al.365 have
reported cyclohexyl-linked tricyclic isoxazoles as potent and selective modulators of the
multidrug resistance protein (MRP1)(XII).
Jie-Fei Cheng et. al.366 have prepared isoxazole derivatives as MCD inhibitors.
Wiles J. A. and co-workers367 have prepared fluoroisothiazolo pyridone derivatives
which exhibited antibacterial activity and inhibitory activities against DNA gyrase and
topoisomerase IV.
With a view to getting better therapeutic value, it was contemplated to synthesise
isoxazole derivatives in corporating pyrazole as parent molecule, to enhance the overall
activity of resulting compounds which have been described as under.

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLES
With a view to achieving better drug potency isoxazole derivatives of type (XII)
have been prepared by the condesation of chalcones of type (I) with hydroxylamine
hydrochloride in the presence of sodium acetate in glacial acetic acid. The chalcones
were synthesised by the condensation of 1,N-phenyl-3-P-ethoxyphenyl-4-formyl
pyrazole with various aromatic ketones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL-
3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Bromophenyl)-3-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 3-(p-Bromophenyl)-5-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-isoxazole
A solution of anhydrous sodium acetate (1.46g, 0.02 M) in a minimum amount
of hot acetic acid was added to a solution of hydroxylamine hydrochloride (1.4 g, 0.02
M) in ethanol (20 ml). This solution was added to a solution of 1-(p-bromophenyl)-3-
(1',N-phenyl-3'-p-ethoxyphenyl-pyrazol-4'-yl)-2-propen-1-one (4.73 g, 0.01 M) in
ethanol (25 ml). The mixture was heated under reflux on waterbath for 12 hrs. The
product was isolated and recrystallised from ethanol.  Yield 68%, m.p. 145oC
(C26H20BrN3O2; Required : C, 64.21; H, 4.14; N, 8.64;  Found : C, 64.15; H, 4.09;
N, 8.58%).
TLC solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly other substituted isoxazoles have been prepared. The physical data
are recorded in Table No. 12.
(E) Antimicrobial  activity of  3-Aryl-5-(1',N-phenyl-3'-p-ethoxyphenyl-
pyrazol-4'-yl)-isoxazoles
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 12.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)














































Alkane C-H str. (asym.) 2974 2975-2950 413
-CH3 C-H str. (sym.) 2869 2880-2860
C-H i.p.def. (asym.) 1458 1470-1435
C-H o.o.p. def. (sym.) 1388 1390-1370
Aromatic C=C str. 1514 1585-1480 414
C-H i.p. def. 1116 1125-1090
C-H o.o.p. def 842 835-810
Pyrazole C=N str. 1614 1630-1590 415
moiety C-N str. 1178 1230-1020
C-Br str. 754 600-800 413
Ether C-O-C str. (asym.) 1240 1275-1200 413
C-O-C str. (sym.) 1055 1075-1020
Isoxazole C=C str. 1514 1580-1530 413
(overlapped)
C=N str. 1614 1470-1460
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)





















1. 1.46-1.50 3H triplet -OCH2CH3 JCH3=6.9
2. 4.10-4.13 2H quartet -OCH2CH3 JCH3=6.8
3. 6.30 1H singlet Ar-Hy -
4. 7.01-7.03 2H doublet Ar-Hgg’ Jgf=8.4
5. 7.34-7.36 2H doublet Ar-Hii’ Jih=8.3
6. 7.47-7.52 3H multiplet Ar-Habd -
7. 7.60-7.67 3H multiplet Ar-He,Ar-Hhh’ -
8. 7.78-7.80 2H doublet Ar-Hff ’ Jfg=8.4
9. 7.90-7.92 1H triplet Ar-Hc -




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
12a C6H5- C26H21N3O2    407  143 0.52 68    10.31      10.26
12b 4-NH2-C6H4- C26H22N4O2 422 198 0.63 73 13.26 13.21
12c 4-Cl-C6H4- C26H20ClN3O2 441.5 167 0.53 68   9.51   9.46
12d 4-Br-C6H4- C26H20BrN3O2    486  145 0.51 68      8.64        8.58
12e 4-F-C6H4- C26H20FN3O2 425 155 0.40 71   9.88   9.83
12f 2-OH-C6H4- C26H21N3O3    423  214 0.54 68      9.92        9.87
12g 4-OH-C6H4- C26H21N3O3    423  233 0.64 65      9.92        9.85
12h 4-OCH3-C6H4- C27H23N3O3    437  175 0.51 83      9.60        9.55
12i 4-CH3-C6H4- C27H23N3O2    421  158 0.59 59      9.97        9.94
12j 3-NO2-C6H4- C26H20N4O4    452  169 0.61 60    12.38      12.34
12k 4-NO2-C6H4- C26H20N4O4    452  118 0.54 78    12.38      12.32
12l 2-C4H3S- C24H19N3O2S    413  201 0.61 59    10.16      10.12
TABLE-12 : PHYSICAL CONSTANTS OF 3-ARYL-5-(1',N-PHENYL-3'-p-ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLES
























B. coccus 18 19 12 16 18 14 21 19 17 18 22 18 25 18 20 22 0
S. aureus 16 21 16 17 13 18 15 19 18 12 18 15 25 19 15 21 0
E. aerogenes 19 17 12 23 19 15 17 20 18 18 16 18 20 21 22 19 0
P. aeruginosa 21 19 10 12 18 21 17 22 16 19 15 15 22 21 16 23 0
A. niger 19 16 14 19 18 15 22 19 12 10 21 17 0 0 0 0 26

























It has been concluded from the experimental data that all the isoxazole derivatives
(XII) markedly inhibit the growth of Gram positive bacteria and Gram negative bacteria.
All compounds showed moderate activity against Gram positive bacteria.
However, maximum activity was observed in compounds bearing R=4-hydroxyphenyl
and 4-nitrophenyl against B.coccus whereas R=4-aminophenyl against S.aureus.
In case of Gram negative bacterial strains, the maximum activity was displayed
by the compounds bearing R=4-bromophenyl against E.aerogenes.While the compounds
with R=phenyl, 4-methoxyphenyl, 2-hydroxyphenyl and 4-methoxyphenyl have shown
considerable activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All compounds exhibited mild activity against A.niger except compound bearing
R=4-hydroxyphenyl and 4-nitrophenyl which showed good activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,benzoylpenicillin,
ciprofloxacin, erythromycin and antifungal activity wascompared with standard drug viz.
greseofulvin.
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Nitriles are reported to possess various therapeutic activities, but due to their
high toxicity, they have low therapeutic importance. The term ‘Nitrile’ was first introduced
by Febung368 in 1844. The first synthesis of nitrile has been reported by Wohler and
Liebig369 in 1832 and Poleuze370 in 1834. They are very much useful as intermediates
for various products such as acrylonitrile for plastic, synthetic rubber, fibers &
phthalonitrile for dye stuff.
SYNTHETIC ASPECTS
Few recent methods for the preparation of nitriles are as mentioned below.
1. From alkyl halides using KCN, tetraalkylammonium salt371 and water in trace.
2. Masanori and Masahiko372 have synthesised nitriles through cyanation of aryl/
heteroaryl bromides employing heterogeneous Pd/C.
3. Stephen A et .al .373 have synthesised E-& Z-cinnamonitr i le  from aryl
aldehyde or ketones in the presence of acetonitrile and potassium hydroxide.
4. Mohanakrishna A. K. and co-workers374 have synthesised nitrile derivatives of
type (III) is as under.
Ar-Br + Zn(CN)2





















The mechanism of nitrle formation  is shown as under.
Reaction between CN and aldehyde is a type of nucleophilic substitution reaction.
From the above reaction, it can be seen that a nucleophile (CN) attacks on the carbonyl
carbon of aldehyde and yields cyanohydrin which reacts with amine to yield nitrile
derivatives.
THERAPEUTIC IMPORTANCE









 Nitriles with fused pyridine ring were reported as ulcer inhibitor383. Kobayashi
et. al.384 have synthesised new derivatives of nitriles. M. C. Dougal385 have synthesised
nitriles and studied their pharmacological activities. Lai Hio Kiong and co-workers6386
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Yogihara and co-workers387 have documented antimicrobial and antiinflammatory
activity of nitriles. Nosyrava et. al.388 have formulated novel nitriles possessing muscle
relaxant activity. Valmajer Juliya et. al.289 have tested some new nitriles as anticonvulsant
agent.Shibata Yasushi and co-workers390 have reported nitriles as insecticides.
Parlo Sanna et. al.391 have synthesised nitriles (V) and screened for their antitubercular
activity.
Iwanowicz E. J. et. al.392 have synthesised nitriles and found preventing and
treating IMPDH associated disorders, such as transplant rejection and autoimmune
disease. Ian J. S. Fairlamb et. al.393 have prepared nitrile derivatives and tested for
their antimicrobial activity. Murakkami Hiroshi et. al.394 have investigated some new





R = Cycloalkyl, alkyl, alkenyl
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Cyanoguanidine derivatives (VII) have been synthesised and reported as inhibitors
of mitochondrial F, FO, ATPase by A. Karnails et al.395 Nurolaini Kifli et. al.396 have
discovered nitriles and reported their antiviral activity.
Recently, Marion Nipper et. al.397 have prepared nitriles useful as antimicrobial
agent. Miroslav Otmar et. al.398 have formulated nitriles possessing antiproliferative
activity. S. Srinivasan et. al.399 have investigated nitriles which showed antimicrobial
activity. Olivier Nicolas and co-workers400 have discovered nitrile derivatives possessing
moderate antimalarial activity. Guohua Zhao et. al.401 have reported Diprolyl nitriles
as potent dipeptidyl peptidase IV inhibitors. Jon Bondebjerg and co-workers402 have
identified a potent and selective inhibitor of human dipeptidyl peptidase I by using a
dipeptide nitrile scaffold.
CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal and H. H. Parekh403 have synthesised newer acetonitriles (VIII)
bearing quinoline moiety and tested them as antimicrobial agent.
Looking to the interesting properties of nitriles, we have synthesised some new
nitriles, which have been described as under.
























SYNTHESIS AND BIOLOGICAL EVALUATION OF a-ARYLAMINO-(1’,N-
PHENYL-3’-p-ETHOXYPHENYL-PYRAZOL-4’-YL)-ACETONITRILES
In view of therapeutic activities of nitriles, it was contemplated to synthesise
some new nitriles in search of agents possessing higher biological activity. Nitriles of
type (XIII) have been synthesised by the reaction of 1,N-Phenyl-3-p-ethoxyphenyl-4-
formyl pyrazole with different aromatic amines in the presence of potassium cyanide and
glacial acetic acid at 0-50C.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF a-ARYLAMINO-(1’,N-
PHENYL-3’-p-ETHOXYPHENYL-PYRAZOL-4’-YL)-ACETONITRILES
(A) Synthesis of p-Ethoxyphenylhydrazone111
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole112
See [A] Part-I, Section-I (B).
(C) Synthesis of a-p-Bromophenylamino-(1’,N-phenyl-3’-p-ethoxyphenyl
pyrazol-4’-yl)acetonitrile
1,N-Phenyl-3-p-ethoxyphenyl-4-formyl pyrazole (2.92 g, 0.01M) dissolved in
ethanol (25ml) was added to potassium cyanide (0.64g, 0.01M) dissolved in water (15
ml) followed by addition of  glacial acetic acid (12 ml). The contents were then stirred
for 5 minutes to form cyanohydrin at 0oC. p-Bromoaniline (1.72g, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were stirred at room temperature
for 24 hrs. The content was poured onto curshed ice. The solid product was filtered and
crystallised from ethanol. Yield 68%, m.p. 168oC (C25H21BrN4O; Required : C,
63.43; H, 4.47; N, 11.84;  Found : C, 63.38; H, 4.42; N, 11.79 %).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted nitriles have been prepared. The physical data are
recorded in Table No. 13.
(E) Antimicrobial activity of a-arylamino-(1’,N-phenyl-3’-p-ethoxyphenyl-
pyrazol-4’-yl)-acetonitriles
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 13.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)

















Alkane C-H str. (asym.) 2916 2975-2950 413
-CH3 C-H str. (sym.) 2854 2880-2860
C-H i.p.def. (asym.) 1448 1470-1435
Aromatic C-H str. 3060 3080-3030
C=C str. 1502 1585-1480 414
C-H i.p. def. 1064 1125-1090
C-H o.o.p. def   837     835-810
Pyrazole C=N str. 1595 1630-1590 415
moiety C-N str. 1159 1230-1020
C-Br str.   759  600-800 413
Ether C-O-C str. (asym.) 1232 1275-1200 414
C-O-C str. (sym.) 1064 1075-1020
(overlapped)
Nitrile CºN str. 2216 2240-2220 420
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)




















1. 1.40-1.45 3H triplet -OCH2CH3 JCH3=6.9
2. 4.02-4.07 2H quartret -OCH2CH3 JCH2=7.0
3. 5.37 1H singlet CHy -
4. 6.72-6.74 2H doublet Ar-Hgg’ Jgf=8.4
5. 6.91-6.93 2H doublet Ar-Hhh’ Jhi=8.7
6. 7.10-7.13 2H doublet Ar-Hae Jab=8.2
7. 7.23-7.36 1H triplet Ar-Hc -
8. 7.47-7.51 2H triplet Ar-Hbd -
9. 7.68-7.70 2H doublet Ar-Hii’ Jih=8.7
10. 7.76-7.78 2H doublet Ar-Hff ’ Jfg=8.4




    (d ppm)
 Relative
No.
Multiplicity Inference    J Value
    In Hz
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    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
TABLE-13 : PHYSICAL CONSTANTS OF a-ARYLAMINO-(1’,N PHENYL-3’-p-ETHOXYPHENYL-PYRAZOL-4’-YL)-
ACETONITRILES
*TLC Solvent System : Acetone : Benzene (1 : 9)
13a C6H5- C25H22N4O    394  169 0.56 64    14.20      14.15
13b 4-Cl-C6H4- C25H21ClN4O 428.5 160 0.52 69 13.06 13.01
   13c 4-CH3-C6H4- C26H24N4O 408 174 0.56 55 12.09 12.04
13d 4-Br-C6H4- C25H21BrN4O    473  168 0.63 68    11.84      11.79
13e 4-F-C6H4- C25H21FN4O 412 165 0.64 60 13.58 13.54
13f 3-Cl,4-F-C6H3- C25H20ClFN4O    446.5  144 0.53 70    12.54      12.49
13g 2-OCH3-C6H4- C26H24N4O2    424  135 0.54 72    13.20      13.15
13h 4-OCH3-C6H4- C26H24N4O2    424  146 0.52 58    13.20      13.14
13i 2-CH3-C6H4- C26H24N4O    408  149 0.50 64    13.72      13.66
13j 3,4-(Cl)2-C6H3- C25H20Cl2N4O    463  198 0.53 64    13.72      13.67
13k 2-NO2-C6H4- C25H21N5O3    439  155 0.73 72    15.94      15.90
























B. coccus 21 17 16 14 16 18 21 16 19 17 21 14 25 18 20 22 0
S. aureus 16 14 20 16 16 17 18 22 20 16 18 16 25 19 15 21 0
E.Aerogenes 17 16 14 18 23 16 18 14 13 18 15 18 20 21 22 19 0
P.aeruginosa 22 19 16 13 14 19 23 16 14 14 22 20 22 21 16 23 0
A. niger 16 13 14 17 18 16 21 22 17 16 16 19 0 0 0 0 26

























It has been concluded from the experimental data that the compounds bearing
R=phenyl, 2-methoxyphenyl and 2-nitrophenyl have displayed good activity against
B.coccus. The compounds bearing R= 4-methoxyphenyl have shown considerable activity
against S.aureus.
In case of Gram negative bacterial strains,  all the compounds were inactive against
Aerogenes except the compound bearing R=4-fluorophenyl. While the compounds
bearing R=phenyl, 2-methoxyphenyl and 4-nitrophenyl showed significant activity against
Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested species.
However, the compounds having R=2-methoxyphenyl and 4-methoxyphenyl displayed
highest activity against A.niger.
The antibacterial activity was compared with standard  drug viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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Microwave radiation is a descriptive term used to identify electromagnetic waves
in frequency spectrum ranging from 1 Giga Hertz (10 Hz) to 30 Giga Hertz. In order to
avoid interfering with radar and telecommunication activites which operate within this
region, most domestic and commercial microwave instruments operate at 2.45 GHz.
These waves represents several interesting and unusual features which not found in other
portions of the electromagnetic spectrum. These features makes “microwaves” uniquely
suitable for several useful applications like industrial, scientific, domestic and medicinal.
The heating effect utilised in microwave assisted organic trasformations is mainly
due to the dielectric polarisation, although conduction losses can also be important
particularly at higher temperatures. Whilst the polaristability of a molecule (determined
by the Debye equation) is the sum of a number of contributions only dipolar and
interfacial polarisation are important to heating effects associated with microwave
irradiation. These include the preparation of sample for analysis404, application to waste
treatment405, polymer technology406, drug release/targeting407,408, and
chemistry409-411.
Microwave induced organic reaction enhancement chemistry is gaining
popularity as a non-conventional technique for rapid organic synthesis, important
features of this technique are easy access to very high temperature , good control over
energy input in a reation and rapid synthesis of organic compounds. The advantages of
microwave induced organic reaction enhancement chemistry include requirement of
simple, in expensive instrument, lesser quantites of solvent and eco-friendly technology.
Microwave heating is distinguished primarily by being radiant process. It’s
relationship to ordinary heat is of much interest. Regular heat rays differ in frequency and
properties. In the conventional method, heat is generated by molecular collosions which
accomplish the energy transfer, while microwave cause heating through the absorption
of energy quanta.
2 8
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Those molecule having dipole moment when submitted to an electric field, they
become aligned. If this field oscillates, the orienatation of molecules, in phase with the
electrical field exacitaiton, cause intense internal heating , upto 1000.C per second,
when powerful waves are used.
The main interests can thus be listed as the rapid trasfer of energy into the bulk of
the reaction mixture, without interia since only the product is heated and the ease of
utiliation. Furthermore, as the depth of penetration in materals is of the same order of
magnitude as the wavelength, microwaves interect with substancess of appreciable
thickness (about 10 cm.)
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute to
the heating effect when the conducting particles are in contact with a non conducting
medium. eg. in heterogenous reactions. It is particularly convenient that qualitatively, the
larger the dielectric constant, the greater the coupling with microwaves. Thus, solvents
such as water, methanol, DMF, ethylacetate, acetone and R-spirit are all heated when
irradiated with microwaves. Non-polar solvents like carbon tetra chloride,
toluene, xylene, benzene do not couple and therefore do not heat with microwave
irradiation.
 Generally, commercial microwave oven is being used in the chemical laboratory
of a frequency of 2450 MHz. The first application of microwave ovens in organic
synthesis began very recently. By the first exeperiments of  Gedye and Giguere, the
evidence for dramatic acceleration in some classical organic reaction, esatblished and
these were ascribed to temperature and pressure effects, when performed in closed teflon
vessels. The reaction can be carried out in teflon, polystyrene and glass vessels since
these are transparent to microwaves. Microwave irradiation has also been applied for
carrying out reactions in open vessels, using organic solvents. The relatively low cost of
modern domestic microwave ovens makes them reasonably readily available to
academic and industrial chemists.
 These experiments sometimes needs solvents which faces some problems with
no safe operation appeared and sometimes explosion results. Therefore, to solve these
problems solvent  free react ion has been developed and to faci l i tate  the
scale-up of preparative runs. Recently, reaction under dry condition using inorganic
2 9
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reagents are ganging more attention because of their enhance selectivity  and milder
conditions than those associated with conventional  homogenous reaction procedures.it
should,be noted that some of inorganic additives reach temperature in excess of 1000.C
very rapidly and decomposition of materials may be problematic, therefore some
precautions regarding superheating and associated fire hazardes or explosions are taken.
 Detail review on “Microwave Assisted Reaction” by S. Caddick412 involves
variety of unusual chemical reactions like,










Successfully loading to the pathway from non traditional approach to the
experimental setup of organic reactions, the concept of “Microwave Induced Organic
Reaction Enhancement” (MORE) chemistry has been utilised for rapid and efficient
synthesis of pyrazolines and methoxy pyridines bearing pyrazole moiety which is
described as under.
SECTION-I : MICROWAVE ENHANCED SYNTHESIS OF 1,N-ACETYL-
3-ARYL-5- [1 ' ,N-PHENYL-3'-p -ETHOXYPHENYL-
PYRAZOL-4'-YL]-PYRAZOLINES
SECTION-III : MICROWAVE ENHANCED SYNTHESIS OF 2-
M E T H O X Y - 3 - C YA N O - 4 - [ 1 ’ , N - P H E N Y L - 3 ’ - p -
ETHOXYPHENYL-PYRAZOL-4’-YL]-6-ARYL PYRIDINES
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ACETYL-3-ARYL-
5-[1',N-PHENYL-3'-p-ETHOXYPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES BY
MICROWAVE ENHANCED SYNTHESIS
As microwave used to create effect in organic synthesis, the “in situ” generation
of heat is very efficient and can be used to significantly reduce reaction times of
synthetically useful organic transformations. Thus microwave assisted organic synthesis
has advantages over conventional techonology. We have synthesised pyrazoline derivatives
of type (III) by the reaction of chalcone with hydrazine hydrate in glacial acetic acid
under microwave irradiation as cited under.
The constitution of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
The compounds of  type (III) have been already synthesised using conventonal
method as reported earlier in Part-I, section-III (D).
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation source
and data are compared in terms of yield and reaction period have been cited in Table
No. 3a.































  2a C6H5- 09 59  07 69 168
2b 4-NH2-C6H4- 08 60  08 74 121
2c 4-Cl-C6H4- 08 70  10 77 087
2d 4-Br-C6H4- 10 72  10 65 093
2e 4-F-C6H4- 09 64  09 70 201
2f 2-OH-C6H4- 08 58  10 70 185
2g 4-OH-C6H4- 10 54  11 73 123
2h 4-OCH3-C6H4- 10 76  10 68 099
2i 4-CH3-C6H4- 11 51  08 65 154
2j 3-NO2-C6H4- 08 74  07 78 111
2k 4-NO2-C6H4- 09 68  08 70 095
2l 2-C4H3S- 10 61  10 73 183
Yield
  %
TABLE NO. 3a : COMPARISON OF CONVENTIONAL METHOD AND
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As a part of our research programme towards the non traditinal approach to the
experimental set up of organic reactions, the concept of “Microwave induced Organic
Reaction Enhancement” (MORE) chemistry has been utilised for rapid and efficient
synthesis of cyanopyridine derivatives of type (VII).The synthesis was carried out by
the condensation of chalcones of type (I) with malononitrile in presence of sodium
methoxide under microwave irradiation as cited under.
The constitution of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
The compounds of  type (VII) have been already synthesised using conventonal
method as reported earlier in Part-VI, section-I (D).
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation source
and data are compared in terms of yield and reaction period have been cited in Table
No. 11a.


















8 - 10 mins.
DMF
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TABLE NO. 11a : COMPARISON OF CONVENTIONAL METHOD AND




We have demonstrated a rapid and general synthesis of acetyl pyrazolines and
methoxy pyridines using a microwave oven. Microwave technology is emerging as an
alternative energy source powerful enough to accomplish chemical transformation in
minutes, instead of hours. Consequently, reactions exhibit cleaner products and more
facile work-up procedures. For this reason, microwave irradiation is presently seeing
an exponential increase in acceptance as a technique for enhancing chemical











  11a C6H5- 09 65  09 70 154
11b 4-OCH3-C6H4- 10 59  10 69 196
11c 4-CH3-C6H4- 08 70  09 75 244
11d 4-Cl-C6H4- 09 63  10 68 186
11e 4-F-C6H4- 08 60  10 65 201
  11f 4-Br-C6H4- 08 62  10 68 168
11g 4-OH-C6H4- 10 69  10 72 199
11h 2-OH-C6H4- 10 70  08 75 180
11i 4-NO2-C6H4- 11 59  10 67 147
11j 3-NO2-C6H4- 10 60  10 64 150
11k 2-C4H3- 10 63  09 69 178
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CH3
C6H5-
4-Cl-C6H4-
4-CH3-C6H3-
4-Br-C6H4-
4-F-C6H4-
3-Cl,4-F-C6H4-
2-OCH3-C6H4-
4-OCH3-C6H4-
2-CH3-C6H4-
3,4-(Cl)2-C6H3-
2-NO2-C6H4-
4-NO2-C6H4-
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